Already, stocks for CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, and Sangamo Therapeutics have tanked over the reports.
|
|
Shares of gene-editing companies CRISPR Therapeutics AG, Editas Medicine Inc, Sangamo Therapeutics Inc and Intellia Therapeutics Inc fell sharply on Monday.
|
|
She serves as chief executive of United Therapeutics, not American Therapeutics.
|
|
" Turning Point Therapeutics: "Turning Point Therapeutics is a very big speculative situation.
|
|
Sorrento Therapeutics and United Therapeutics are licensing immunotherapy assets to be developed jointly.
|
|
CRISPR Therapeutics Intellia Therapeutics and Caribou Biosciences are all parties to the appeal.
|
|
Stock prices of three CRISPR companies—Editas Medicine, Intellia Therapeutics and CRISPR Therapeutics—tumbled.
|
|
" United Therapeutics — An analyst at Credit Suisse upgraded United Therapeutics to "outperform" from "neutral.
|
|
Equator Therapeutics: Equator Therapeutics is developing a drug to help users burn calories without exercise.
|
|
Pear Therapeutics is part of a burgeoning category of health start-ups known as digital therapeutics.
|
|
Crescita Therapeutics Inc: * CRESCITA THERAPEUTICS ANNOUNCES MEASURES IN RESPONSE TO COVID-19 VIRUS * CRESCITA THERAPEUTICS INC - WILL BE TEMPORARILY CLOSING ITS OFFICE AND PRODUCTION FACILITY IN LAVAL, QUÉBEC, * CRESCITA THERAPEUTICS INC - FACILITY CLOSURE WILL RESULT IN TEMPORARY LAYOFFS AFFECTING MOST PRODUCTION AND OFFICE PERSONNEL * CRESCITA THERAPEUTICS INC - PRODUCT DISTRIBUTION THROUGH COMPANY'S THIRD-PARTY LOGISTICS PROVIDER WILL REMAIN OPERATIONAL WITH REDUCED CAPACITY.
|
|
Also corrects source to "Convelo Therapeutics" from "Roche Holding AG") July 16 (Reuters) - CONVELO THERAPEUTICS: * CONVELO THERAPEUTICS ENTERS INTO COLLABORATION AND OPTION TO ACQUIRE AGREEMENT WITH GENENTECH TO DISCOVER NOVEL REMYELINATING THERAPIES * CONVELO THERAPEUTICS - CONVELO WILL RECEIVE AN UNDISCLOSED UPFRONT PAYMENT AND RESEARCH SUPPORT FROM GENENTECH.
|
|
Fulcrum Therapeutics Inc: * FULCRUM THERAPEUTICS ANNOUNCES COMPLETE DATA FROM PHASE 1 TRIAL WITH LOSMAPIMOD IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) * FULCRUM THERAPEUTICS INC - LOSMAPIMOD ACHIEVES TARGET ENGAGEMENT IN MUSCLE * FULCRUM THERAPEUTICS INC - LOSMAPIMOD WAS WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS Source text for Eikon: Further company coverage:
|
|
Nivien Therapeutics: Nivien Therapeutics is developing the first small molecule drugs to enhance both chemo and immunotherapies.
|
|
RA picked up Sage Therapeutics and Axsome Therapeutics, which are developing drugs for central nervous system disorders.
|
|
"This is the moment for digital therapeutics," said Corey McCann, the founder and CEO of Pear Therapeutics.
|
|
CytomX Therapeutics Inc: * CYTOMX THERAPEUTICS ANNOUNCES APPOINTMENT OF CARLOS CAMPOY AS CHIEF FINANCIAL OFFICER * CYTOMX THERAPEUTICS - ANNOUNCED APPOINTMENT OF CARLOS CAMPOY AS SENIOR VICE PRESIDENT & CFO Source text for Eikon: Further company coverage:
|
|
Shares of CRISPR Therapeutics tanked nearly 13 percent, shares of Editas Medicine dropped nearly 8 percent, shares of Intellia Therapeutics fell nearly 10 percent, while shares of Sangamo Therapeutics shed more than 5 percent.
|
|
But that's not stopping a number of biotech companies from capitalizing on the technology: Crispr Therapeutics, Caribou Biosciences (and spinoff Intellia Therapeutics), and Editas Medicine all hope to use the technique to develop human therapeutics.
|
|
The largest offering was for Rubius Therapeutics, a developer of red cell therapeutics, followed by cybersecurity provider Carbon Black.
|
|
Plus Therapeutics Inc: * PLUS THERAPEUTICS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:
|
|
Naturally, Celgene led the latest round, with cash infusions from United Therapeutics Corporation, Sorrento Therapeutics and Human Longevity, Inc.
|
|
ArTara Therapeutics Inc: * ARTARA THERAPEUTICS APPOINTS BLAINE DAVIS AS CHIEF FINANCIAL OFFICER * ARTARA THERAPEUTICS INC - ANNOUNCED APPOINTMENT OF BLAINE DAVIS AS CHIEF FINANCIAL OFFICER EFFECTIVE FEBRUARY 11, 2020 * ARTARA THERAPEUTICS - DAVIS MOST RECENTLY SERVED AS VICE PRESIDENT, HEAD OF INVESTOR RELATIONS AND CORPORATE COMMUNICATIONS AT INSMED Source text for Eikon: Further company coverage:
|
|
For example, three early clinical-stage startup companies, all based on CRISPR technology, have struck major alliances with big pharma and biotech companies: Editas Medicine (Juno Therapeutics), CRISPR Therapeutics (Vertex and Celgene) and Intellia Therapeutics (Novartis).
|
|
BioMarin Pharmaceuticals Inc, Sarepta Therapeutics Inc and PTC Therapeutics Inc are leading the development of a drug for the disorder.
|
|
Last week, Sarepta Therapeutics Inc beefed up its gene therapy portfolio through the purchase of its partner Myonexus Therapeutics, while Swiss drugmaker Roche said it was buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion.
|
|
Four companies—Frequency Therapeutics, Decibel Therapeutics, Akouos, and Sound Pharmaceuticals—are all developing drugs to treat different types of hearing loss.
|
|
Four companies — Frequency Therapeutics, Decibel Therapeutics, Akouos, and Sound Pharmaceuticals — are all developing drugs to treat different types of hearing loss.
|
|
" Pear Therapeutics is at the forefront of a new category of medical treatment, offering what company executives call "prescription digital therapeutics.
|
|
Celgene, United Therapeutics, Sorrento Therapeutics, Human Longevity, the Dreyfus Family Office and Section 222 took part in the series-A funding.
|
|
Given the difficulty developing traditional therapeutics, the likelihood of the next blockbuster treatment or cure emerging from digital therapeutics is ever-increasing.
|
|
Last week, Sarepta Therapeutics Inc beefed up its gene therapy portfolio through the purchase of its partner Myonexus Therapeutics Inc, while Swiss drugmaker Roche Holding AG said it was buying U.S.-based gene therapy specialist Spark Therapeutics Inc for $4.3 billion.
|
|
United Therapeutics —United Therapeutics fell around 5.7% after the company announced its clinical study of esuberaprost tablets did not meet its primary endpoint.
|
|
Corey McCann is the CEO of Pear Therapeutics, a company developing prescription digital therapeutics for conditions like substance use disorder and multiple sclerosis.
|
|
Agree to combine * Nivalis therapeutics inc - merger will result in a combined company * Nivalis Therapeutics Inc - Alpine will merge with a wholly-owned subsidiary of nivalis in an all-stock transaction * Nivalis Therapeutics-Frazier Healthcare Partners, Alpine Bioventures, Orbimed Advisors to invest additional $17 million into Alpine Immune Sciences * Nivalis Therapeutics Inc - following merger, current alpine shareholders will own approximately 74 percent of combined company * Nivalis Therapeutics Inc - transaction has been approved by board of directors of both companies * Nivalis Therapeutics Inc - upon closing of transaction, name of combined company will become Alpine Immune Sciences Inc Source text for Eikon: Further company coverage:
|
|
Odonate Therapeutics Llc: * ODONATE THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING * ODONATE THERAPEUTICS LLC- ANNOUNCED PRICING OF ITS INITIAL PUBLIC OFFERING OF 6.25 MILLION SHARES OF COMMON STOCK AT A PUBLIC OFFERING PRICE OF $24.00 Source text for Eikon: Further company coverage:
|
|
Shares of other companies using gene-editing technologies, CRISPR Therapeutics, Editas Medicine and Intellia Therapeutics, fell between 7 and 10 percent in afternoon trading.
|
|
Pfizer already has collaboration agreements with gene therapy companies including Spark Therapeutics and Sangamo Therapeutics to target conditions like hemophilia and certain neurodegenerative disorders.
|
|
Spark Therapeutics — Spark Therapeutics gained 2.6% after a $4.3 billion buyout plan from Swiss drugmaker Roche received regulatory approval in the U.K. to proceed.
|
|
Nektar Therapeutics — Nektar Therapeutics plunged more than 30% Friday after the company revealed manufacturing errors for a cancer drug that is currently in clinical trial.
|
|
Allergan became a top NASH contender with its acquisition of Tobira Therapeutics and a deal with private Akarna Therapeutics on the same day last year.
|
|
In the past several months, two private biotechs, cancer drugmaker Peloton Therapeutics and cell-therapy company BlueRock Therapeutics, were both sold to big pharma companies.
|
|
Round size and year: $276 million in 2019More about ADC Therapeutics: The cancer-focused ADC Therapeutics was founded in 2011 and is based in Switzerland.
|
|
Seres Therapeutics Inc: * SERES THERAPEUTICS INC FILES FOR COMMON STOCK OFFERING OF UP TO $25.0 MILLION - SEC FILING Source text for Eikon: Further company coverage:
|
|
Some of his targets have included, Acorda Therapeutics, Biogen, Hoffman-La Roche, Bristol-Myers, Aegerion, Jazz Pharmaceuticals, Insys Therapeutics, Anacor Pharmaceuticals, Shire, Pozen, and Celgene.
|
|
Pear Therapeutics, another Boston outfit, makes "digital therapeutics" — essentially apps that use cognitive behavioral therapy techniques to help recovering addicts stick with their treatment programs.
|
|
Viking Therapeutics is looking to validate a potential blockbuster treatmentAnalysts at SVB Leerink expect more data from Viking Therapeutics in the second half of 2020.
|
|
Pear Therapeutics, a digital therapeutics company working on apps for substance use disorders, just lost a key partnership with Sandoz, the generics division of Novartis.
|
|
This year, the Swiss drug giant Roche spent nearly $5 billion to acquire Spark Therapeutics, a biotech selling a gene therapy that cures a type of blindness and researching others, including treatments for hemophilia; the rare-disease biotech Sarepta Therapeutics bought a gene-therapy startup called Myonexus Therapeutics for $165 million; and the biopharma Biogen bought a gene-therapy biotech, Nightstar Therapeutics, for about $800 million.
|
|
Two young startups to watch — they have strong founders and top venture backing on their side — are Frequency Therapeutics and Decibel Therapeutics, both based in Boston.
|
|
Some of the firm's bets include the cancer drug developer Bicycle Therapeutics, and Spero Therapeutics, which is working on antibiotics to treat drug-resistant bacterial infections.
|
|
He has been adding to his position in Nektar Therapeutics, which is developing in abuse-proof opioid medication, and gene-therapy drug maker Spark Therapeutics Inc.
|
|
Some of the firm's biggest holdings — like the biotech companies Global Blood Therapeutics and Mirati Therapeutics — fell in August but have rebounded so far in September.
|
|
Appili Therapeutics Inc: * APPILI THERAPEUTICS ANNOUNCES PRICING OF OVERNIGHT MARKETED EQUITY OFFERING * APPILI THERAPEUTICS INC - APPILI WILL ISSUE MINIMUM OF 6.3 MILLION UNITS OF CO AND MAXIMUM OF 8.8 MILLION UNITS AT A PRICE OF C$0.80 PER UNIT Source text for Eikon: Further company coverage:
|
|
Firms such as CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine have been built on the idea that it could be used to develop treatments for human diseases.
|
|
Altay Therapeutics: Located inside the Bayer Collaborator in San Francisco, Altay Therapeutics has developed small molecule therapies that block disease-causing DNA-binding proteins (or transcriptional regulators).
|
|
By contrast, shares of Intellia Therapeutics and Crispr Therapeutics, which have licenses to the intellectual property from Dr. Doudna and her colleagues, each fell nearly 10 percent.
|
|
A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Italy * Orexigen Therapeutics Inc- Under terms of agreement, Bruno will be responsible for all commercialization activity and expenses * Orexigen Therapeutics Inc says Bruno expects that Mysimba will be available for patients in Italy in Q4 of this year * Orexigen Therapeutics Inc - Orexigen Therapeutics Ireland, Bruno Farmaceutici executed a distributorship agreement for Mysimba in Italy * Orexigen Therapeutics-Under deal co to supply Mysimba to Bruno for negotiated transfer price, upfront milestone payments at signing, first commercial sale Source text for Eikon: Further company coverage:
|
|
The Gates Foundation just launched the COVID-19 Therapeutics Accelerator, a global effort to speed the discovery and development of therapeutics for COVID-19 through multi-stakeholder collaboration.
|
|
Y-mAbs Therapeutics, Inc: * Y-MABS ANNOUNCES POSITIVE PRE-BLA MEETING WITH FDA FOR OMBURTAMAB * Y-MABS THERAPEUTICS, INC - EXPECTS TO COMPLETE ROLLING BLA WITHIN APPROXIMATELY 10 WEEKS.
|
|
As a result, Gwirtzman has been moving into biotech companies Revance Therapeutics Inc and Esperion Therapeutics Inc that have been hurt by investor skittishness over the healthcare sector.
|
|
RECEIVES A COMPLETE RESPONSE LETTER FROM THE FDA FOR TWIRLA® (AG200-15) FOR THE PREVENTION OF PREGNANCY * AGILE THERAPEUTICS - CRL STATES THAT FDA HAS DETERMINED THAT IT CANNOT APPROVE NDA FOR TWIRLA ITS PRESENT FORM * AGILE THERAPEUTICS INC - CRL IDENTIFIES DEFICIENCIES RELATING TO QUALITY ADHESION TEST METHODS * AGILE THERAPEUTICS-FDA INDICATED APPLICABLE SECTIONS OF AMENDED NDA SUBMITTED BY CO COULD BE INCORPORATED WHEN RESPONDING TO DEFICIENCIES NOTED IN CRL * AGILE THERAPEUTICS - CRL ALSO NOTED THAT OBSERVATIONS IDENTIFIED DURING INSPECTION OF A FACILITY OF CORIUM INTERNATIONAL FOR TWIRLA NDA MUST BE RESOLVED * AGILE THERAPEUTICS INC - CRL DOES NOT IDENTIFY ANY SPECIFIC ISSUES RELATING TO SAFETY OF TWIRLA * AGILE THERAPEUTICS SAYS CRL RECOMMENDS THAT CO ASSESS IN VIVO ADHESION PROPERTIES DEMONSTRATED IN SECURE CLINICAL TRIAL * AGILE THERAPEUTICS - CRL "QUESTIONS" THE IN VIVO ADHESION PROPERTIES OF TWIRLA & THEIR POTENTIAL RELATIONSHIP TO SECURE PHASE 3 CLINICAL TRIAL RESULTS * AGILE THERAPEUTICS INC - "WE ARE EVALUATING THE FDA'S RESPONSE" Source text for Eikon: Further company coverage:
|
|
CRANBURY, N.J. – CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc.
|
|
By the close of trading Tuesday, Editas Medicine was down nearly 12 percent, Crispr Therapeutics fell more than 5 percent, and Intellia Therapeutics had plunged to just over 14 percent.
|
|
S: * TG THERAPEUTICS AND NOVIMMUNE SA ANNOUNCE GLOBAL AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF A NOVEL ANTI-CD47/ ANTI-CD19 BISPECIFIC ANTIBODY * TG THERAPEUTICS INC - COMPANIES WILL JOINTLY DEVELOP PRODUCT ON A WORLDWIDE BASIS, FOCUSING ON INDICATIONS IN AREA OF HEMATOLOGIC B-CELL MALIGNANCIES * TG THERAPEUTICS - CLINICAL TRIALS ON TG-1801 ARE EXPECTED TO COMMENCE LATER THIS YEAR OR EARLY IN 2019 * TG THERAPEUTICS - TO MAKE UP-FRONT & MILESTONES PAYMENTS BASED ON EARLY CLINICAL DEVELOPMENT * TG THERAPEUTICS - TO BE RESPONSIBLE FOR COSTS OF CLINICAL DEVELOPMENT OF PRODUCTS THROUGH END OF PHASE II Source text for Eikon: Further company coverage:
|
|
Those seven are: Intercept Pharmaceuticals, Genfit, NGM Biopharmaceuticals, Akero Therapeutics, Viking Therapeutics, Inventiva Pharma, and 89bio2019 crumbled into a "graveyard of failures" in NASH, as one Wall Street analyst put it.
|
|
" Juno Therapeutics: "We don't do the clinical stages anymore.
|
|
" Cara Therapeutics: "This stock is too hot for me.
|
|
ATLANTA, July 05, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc.
|
|
ATLANTA, July 12, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc.
|
|
" Sarepta Therapeutics: "We have now missed that stock, sir.
|
|
HELSINKI (Reuters) - U.S. biotechnology company Acorda Therapeutics Inc. (ACOR.
|
|
GS. May 203: G1 Therapeutics (US, biotech) – $106.3m IPO.
|
|
" Adaptimmune Therapeutics: "Man, come on, you speculated, you won.
|
|
Therapeutics — Drugs that lessen the severity of disease symptoms.
|
|
Style ____ Insys Therapeutics paid millions of dollars to doctors.
|
|
" Sage Therapeutics: "I am a believer in [CEO] Jonas.
|
|
" Corcept Therapeutics: "Oh man, the stock's up 100 percent.
|
|
" Crispr Therapeutics: "Come on, man, that's way too speculative.
|
|
" Corcept Therapeutics: "They've been trying to do psychiatric disorders.
|
|
BOSTON (Reuters) - North Carolina sued Insys Therapeutics Inc INSY.
|
|
Bayer bought a 12.8 percent share in U.S.-based Crispr Therapeutics, with whom it already has a joint venture for new breakthrough therapeutics to cure blood disorders, blindness and congenital heart disease.
|
|
Firms such as Caribou Biosciences, CRISPR Therapeutics and Intellia Therapeutics are also pursuing commercial applications of the approach; these either hold or license a patent filed by Dr Doudna that is pending.
|
|
Some of these include Aimmune Therapeutics, whose treatment to protect children with food allergies is seeking FDA approval; Puma Biotech and Juno Therapeutics, both of which have gone recent public in recent years; and Intarcia Therapeutics, which makes a matchstick-size, diabetes-treating pump and was flying high two years ago, though it has more recently taken its lumps.
|
|
Cara Therapeutics — Cara Therapeutics surged 20% after the biopharmaceutical company announced positive results for a Phase 3 trial of a clinical study for its medication, Korsuva, an injection for patients with kidney disease.
|
|
United Therapeutics— United Therapeutics shares rose 5% after a Credit Suisse upgraded the biotechnology company to outperform from neutral and raised his price target on the stock to $101 from $98 per share.
|
|
In an industry with ubiquitous mission statements that call for "lifesaving therapeutics" or "innovative new solutions," there seems to be a major lack of innovation or therapeutics for diseases that are not profitable.
|
|
According to the settlement agreement, United Therapeutics routinely obtained data from the charity about how many patients on United Therapeutics' drugs it assisted, which the drugmaker used to decide how much to donate.
|
|
Akero Therapeutics is testing 'one of the most interesting NASH drug classes'Akero Therapeutics is testing a similar idea to NGM Bio — their drugs use the same mechanism called the fibroblast growth factor (FGF).
|
|
Juno Therapeutics, another company working on CAR-T, spiked 22016 percent but settled back and was up 210 percent Thursday, while Nektar Therapeutics, which is developing similar immunotherapy drugs, rose nearly 8 percent.
|
|
Hariri became head of the Celgene's new Cellular Therapeutics Division.
|
|
" Esperion Therapeutics: "Boy, that one is back from the dead.
|
|
Last but not least we have healthcare stock Sarepta Therapeutics.
|
|
The pharmaceutical company Insys Therapeutics manufactures both Marinol and Syndros.
|
|
CRANBURY, N.J., July 12, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc.
|
|
HAIFA, Israel, July 11, 5123 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
|
|
Correction: An earlier version mischaracterized EpiBiome's approach to microbiome therapeutics.
|
|
Bringing traditional therapeutics to market is becoming exponentially more expensive.
|
|
NEW YORK, July 225, 29 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc.
|
|
Therapeutics and diagnostics are two key applications for microbiome research.
|
|
" Sarepta Therapeutics: "OK, I think the move has been made.
|
|
Executives from Cigna, CVS, Humana, OptumRx and Prime Therapeutics testified.
|
|
Sarepta Therapeutics' stock closed up more than 36 percent Tuesday.
|
|
Novartis sided with Penn, and Juno Therapeutics with St. Jude.
|
|
" Corcept Therapeutics Incorporated: "Look, this is a very tough area.
|
|
Even with therapeutics, the virus could still spread, infecting millions.
|
|
This is, you mentioned the AbCellera therapeutics collaboration we have.
|
|
" Flexion Therapeutics: "Oh, man that thing is just on fire.
|
|
" Karuna Therapeutics: "Mental health is almost impossible to get right.
|
|
" PTC Therapeutics: "You've got yourself a real binary situation there.
|
|
The treatment is called Luxturna and made by Spark Therapeutics.
|
|
Difficile infection * Seres Therapeutics Inc - based on recent fda interactions, new ser-109 clinical study is to be designated a phase 3 trial * Seres Therapeutics Inc - phase 3 trial initiation triggers a $20 million milestone payment from nestlé health science * Seres Therapeutics - plans to accelerate interactions with european regulatory agencies in coming months for ser-109 product approval across europe * Seres Therapeutics Inc - company expects that single pivotal study may support ser-109 registration and approval Source text for Eikon: Further company coverage:
|
|
Previously, Celniker was the president and CEO of Taligen Therapeutics from 2008 to 2011, when Taligen Therapeutics was acquired by Alexion Pharmaceuticals; following the acquisition, she served as Alexion's executive vice president, translational medicine.
|
|
When I mentioned that to Pear Therapeutics CEO Corey McCann, he imparted the one question he asks pharma companies to see if they&aposre really serious about incorporating things like digital therapeutics into their businesses.
|
|
Venomyx Therapeutics: Venomyx is creating a universal recombinant antivenom for snakebite.
|
|
Sage Therapeutics dropped more than 2 percent during the extended session.
|
|
These nice blue Earth Therapeutics Spa Socks are $5 at Target.
|
|
The study was funded by Obalon's parent company, Obalon Therapeutics, Inc.
|
|
Its paying customers include Beam Therapeutics, Regeneron Pharmaceuticals, Zoetis and Zymergen .
|
|
BOSTON (Reuters) - The former chief executive of Insys Therapeutics Inc INSY.
|
|
Insys Therapeutics did not immediately respond to CNBC's request for comment.
|
|
BERKELEY HEIGHTS, N.J., July 22017, 275 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc.
|
|
It invests primarily in Europe, with a particular focus on therapeutics.
|
|
United Therapeutics has an office and manufacturing facility outside of Durham.
|
|
Proteostasis Therapeutics slipped 8.93 percent and Galapagos 2.88 percent on Tuesday.
|
|
Round size and year: $250 million, 2019 More about Anthos Therapeutics:
|
|
PTC Therapeutics did not immediately respond to a request for comment.
|
|
Insys Therapeutics Inc, Cook County Circuit Court, Chancery Division, No. 2016CH11216.
|
|
"You need good tools to find the right therapeutics," he said.
|
|
Other biotech and pharma companies are scrambling to craft new therapeutics.
|
|
A Boston jury found executives of Insys Therapeutics guilty of racketeering.
|
|
Crispr Therapeutics fell by 13 percent shortly after the scientists' announcement.
|
|
All three of these firms specialize in messenger RNA (mRNA) therapeutics.
|
|
John Kapoor, 85033, of Insys Therapeutics, was arrested Thursday in Arizona.
|
|
We urgently need to develop next-generation diagnostics, vaccines and therapeutics.
|
|
NEW YORK, Jan 122.483 (IFR) - Adaptimmune Therapeutics (UK, biotech) – $122.473m ABB.
|
|
The therapeutics team was not impacted by the layoffs, he said.
|
|
" Juno Therapeutics: "Look, that's one of the high-risk immunotherapy stocks.
|
|
Venrock has backed health companies ranging from Castlight to Juno Therapeutics.
|
|
Based in Research Triangle Park, N.C., Locus is commercializing research initially developed by scientists at North Carolina State University that focused on Cas3 proteins, which devour DNA Pac-Man-style, rather than edit it like the more well-known Cas9-based CRISPR technologies being used by companies like Caribou Biosciences, Editas Medicine, Synthego, Intellia Therapeutics, CRISPR Therapeutics and Beam Therapeutics.
|
|
Nektar Therapeutics – Shares of Nektar Therapeutics tanked nearly 11%, extending its slide after the company said in an earnings call Thursday evening it had manufacturing errors for a cancer drug that is currently in clinical trial.
|
|
S. LICENSING AGREEMENT TO COMMERCIALIZE KORSUVA™ INJECTION IN DIALYSIS PATIENTS WITH PRURITUS * CARA THERAPEUTICS INC - CARA ELIGIBLE FOR UP TO $470 MILLION IN REGULATORY AND COMMERCIAL MILESTONES * CARA THERAPEUTICS INC - VFMCRP TO COMMERCIALIZE KORSUVA INJECTION WORLDWIDE EXCEPT IN U.S., JAPAN AND SOUTH KOREA * CARA THERAPEUTICS INC - CARA RECEIVES UPFRONT PAYMENT OF $50 MILLION IN CASH AND AN EQUITY INVESTMENT OF $20 MILLION * CARA THERAPEUTICS INC - CARA IS ELIGIBLE TO RECEIVE TIERED ROYALTIES BASED ON NET SALES OF KORSUVA INJECTION IN LICENSED TERRITORIES * CARA THERAPEUTICS INC - CARA WILL SOLELY PROMOTE KORSUVA INJECTION IN ALL NON-FMC CLINICS IN U.S. AND RETAIN ALL PROFITS FROM THOSE SALES Source text for Eikon: Further company coverage:
|
|
Sorrento Therapeutics Inc: * SORRENTO LAUNCHES NOVEL I-CELL™ COVID-19 CELLULAR VACCINE PROGRAM * SORRENTO THERAPEUTICS INC - I-CELL VACCINE IS EXPECTED TO ELICIT BOTH T CELL AND B CELL IMMUNITIES AGAINST SARS-COV-2 * SORRENTO THERAPEUTICS INC - INTENDS TO SUBMIT A FULL PACKAGE FOR AN IND FILING THAT WOULD ENABLE HUMAN CLINICAL TRIALS TO START AS SOON AS POSSIBLE * SORRENTO THERAPEUTICS INC - IN DISCUSSIONS WITH FDA'S CENTER FOR BIOLOGICS EVALUATION & RESEARCH UNDER IND#019724 FOR REQUIRED IND-ENABLING STUDIES * SORRENTO THERAPEUTICS INC - BELIEVES IT MAY BE IN A POSITION TO INITIATE HUMAN VACCINATION TRIALS AS EARLY AS MID-YEAR 2020 FOR COVID-19 VACCINE Source text for Eikon: Further company coverage:
|
|
But last May, a small case study suggested the much-hyped technology might actually be quite dangerous—and pop went the Crispr bubble, briefly tanking shares of Crispr companies like Editas Medicine, Intellia Therapeutics, and Crispr Therapeutics.
|
|
Nektar Therapeutics also rallied after researchers presented data at ASCO on Saturday.
|
|
The drug costs $34,343 per patient without insurance, according to Sage Therapeutics.
|
|
" Seres Therapeutics Inc: "I think that one is a buy, buy, buy.
|
|
NEW YORK, Feb 1053 (IFR) - PRICED Beam Therapeutics (US, biotech) – $1043m IPO.
|
|
NEW YORK, Feb 1073 (IFR) - PRICED Beam Therapeutics (US, biotech) – $1063m IPO.
|
|
MONTREAL and NEW YORK, July 27012, 2016 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc.
|
|
This press release and any statements of representatives of Edge Therapeutics, Inc.
|
|
BR for $4.8 billion - Celgene's $9 billion buyout of Juno Therapeutics JUNO.
|
|
Nektar Therapeutics' stock is down more than 20 percent year to date.
|
|
Consumers are discovering digital therapeutics, and the treatments are already transforming lives.
|
|
Take Juno Therapeutics, founded in Seattle in 2013 to develop immunotherapy drugs.
|
|
Representatives for Tesaro and Sarepta Therapeutics were not immediately available to comment.
|
|
But Rodelis Therapeutics tried to increase the cost of Cycloserine 22-fold.
|
|
"There is a global market for cannabinoid-derived therapeutics," Yew told CNBC.
|
|
It was created by InVivo Therapeutics, a biotechnology startup in Cambridge, Massachusetts.
|
|
Today the cancer therapeutics space is worth more than $100 billion globally.
|
|
" Aimmune Therapeutics: "I've looked at this company and we did like it.
|
|
" Crispr Therapeutics AG: "This is a very, very exciting gene-based company.
|
|
Go deeper: Watch an Astraea Therapeutics video of Zaveri explaining the findings.
|
|
" Esperion Therapeutics: "It's fine, it's just that we got to be careful.
|
|
" Aimmune Therapeutics: "It's speculative and people have crushed all the speculative stocks.
|
|
Other biotechs developing mRNA coronavirus vaccines include Moderna, BioNTech, and Arcturus Therapeutics.
|
|
Glybera is no longer available and GSK sold Strimvelis to Orchard Therapeutics.
|
|
You're going to say: 'Why didn't i buy a little Sage Therapeutics?
|
|
NEW YORK, Jan 122.43 (IFR) - Black Diamond Therapeutics (US, biotech) - $201.2m IPO.
|
|
Following AnapstysBio's good news, shares of Aimmune Therapeutics fell nearly 2 percent.
|
|
Shares of Juno Therapeutics soared more than 34 percent on the news.
|
|
For Melinta Therapeutics based in Morristown, N.J., the future is even grimmer.
|
|
Similar CAR-T treatments are being developed by Juno Therapeutics Inc JUNO.
|
|
Announces proposed offering of units * Antibe therapeutics inc - proposed offering of units for minimum gross proceeds of $3 million and maximum gross proceeds of $5 million * Antibe therapeutics inc - has filed a preliminary short form prospectus in connection with a proposed marketed offering of units of company * Antibe therapeutics inc - intends to use net proceeds to complete its phase 2 gi safety study for company's lead drug, atb-346 * Antibe therapeutics inc - also intends to use net proceeds to commence metabolic studies for atb-346 Source text for Eikon: Further company coverage:
|
|
Rubius Therapeutics Inc: * RUBIUS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND ANNOUNCES STRATEGIC FOCUS ON ONCOLOGY AND AUTOIMMUNITY * Q4 EARNINGS PER SHARE ESTIMATE $-0.60 — REFINITIV IBES DATA * RUBIUS THERAPEUTICS - COMPANY IS DEPRIORITIZING RTX-134 PROGRAM FOR TREATMENT OF PHENYLKETONURIA (PKU) AND ITS OTHER RARE DISEASE PROGRAMS * CASH RUNWAY WILL BE EXTENDED INTO 2022 Source text for Eikon: Further company coverage:
|
|
PROVIDES REGULATORY UPDATE ON TWIRLA® (AG200-15) FOR THE PREVENTION OF PREGNANCY * AGILE THERAPEUTICS - ANNOUNCED CONTENT OF OFFICIAL MINUTES FROM TYPE A MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION HELD ON APRIL 16 * AGILE THERAPEUTICS INC - IN CRL, FDA INFORMED COMPANY THAT TWIRLA NDA COULD NOT BE APPROVED * AGILE THERAPEUTICS - IN OFFICIAL MINUTES, FDA INFORMED CO IT CONTINUES TO HAVE SIGNIFICANT CONCERNS REGARDING ADHESION OF TWIRLA * AGILE THERAPEUTICS INC - FDA ALSO INFORMED CO IT WOULD NEED TO DEMONSTRATE BIOEQUIVALENCE TO DATA AND INFORMATION FOR ORIGINAL FORMULATION * AGILE - FDA SAID CO NEEDS TO ADDRESS TWIRLA ADHESION PROPERTIES BY REFORMULATING TRANSDERMAL SYSTEM, CONDUCT FORMAL ADHESION STUDY WITH NEW FORMULATION * AGILE THERAPEUTICS - FDA SAID AFTER CO SATISFIES QUESTIONS ON ADHESION, ADEQUATELY BRIDGES TO FINDINGS IN SECURE PHASE 3 TRIAL, IT ANTICIPATES DISCUSSING SAFETY & EFFICACY OF TWIRLA * AGILE THERAPEUTICS INC - TO EXTENT THAT CO REFORMULATES TWIRLA, IT MAY CREATE NEED FOR ADDITIONAL MANUFACTURING WORK AND REVIEW BY FDA * AGILE THERAPEUTICS INC - WHILE CO WILL CONTINUE TO EVALUATE ALL OPTIONS ON NEXT STEPS, EXPECT CO WILL PURSUE FORMAL DISPUTE RESOLUTION.
|
|
The winner was Arthro Therapeutics, followed by Peppy Pals and MIND Music Labs.
|
|
But Zulresso's manufacturer, Sage Therapeutics, expects the drug to be covered under insurance.
|
|
She receives funding from The Limb Preservation Foundation, Aratana Therapeutics and Allosource Inc.
|
|
The idea is similar to another Founders Fund portfolio company – Emerald Lab Therapeutics.
|
|
Kulkarni said the incident hadn't had a major impact on CRISPR Therapeutics' business.
|
|
Aurora is also trying to buy medical marijuana company CanniMed Therapeutics Inc CMED.
|
|
A spokesperson for Knight Therapeutics said the company does not comment on rumors.
|
|
TORONTO (Reuters) - Highland Therapeutics Inc has raised $200 million from Morgan Stanley (MS.
|
|
This new range of products is being commonly referred to as digital therapeutics.
|
|
S) Roche's delayed $4.3 billion takeover of gene therapy maker Spark Therapeutics (ONCE.
|
|
Allergan's agreement on Tuesday to acquire liver drug developer Tobira Therapeutics Inc TBRA.
|
|
" Acorda Therapeutics: "Biotech right now is totally on the hit list for politicians.
|
|
The Promise for Antibiotics and Therapeutics for Health (PATH) Act, sponsored by Sens.
|
|
CRISPR Therapeutics says it is also thinking about going public, given investors' interest.
|
|
NuvoAir is a new digital therapeutics startup that is also tackling this problem.
|
|
Dr. Rothblatt said the effects of the law on United Therapeutics were immediate.
|
|
Alexion Pharmaceuticals (ALXN) is offering $788 million for Swedish drug maker Wilson Therapeutics.
|
|
Alexion Pharmaceuticals – Alexion is offering $788 million for Swedish drug maker Wilson Therapeutics.
|
|
One of the last IPOs of 2017 is San-Francisco-based Denali Therapeutics.
|
|
At least one company focusing on a cannabis-related products, Insys Therapeutics INSY.
|
|
Luxturna was developed and is commercialized in the United States by Spark Therapeutics.
|
|
" Crispr Therapeutics: "Oh jeez, it's another one that has just run so much.
|
|
United Therapeutics paid a $210 million settlement late last year for similar allegations.
|
|
She also sits on the boards of DreamWorks Animation, Juno Therapeutics and Costco.
|
|
Moderna Therapeutics has two big pharmaceutical partnerships to bring its products to market.
|
|
Bezos Expeditions has invested in businesses including Basecamp, Juno Therapeutics, Workday and Twitter.
|
|
Other companies developing CAR T-cell therapies include Juno Therapeutics Inc and Novartis.
|
|
Earlier in his career, he served as Independent Director at Cara Therapeutics, Inc.
|
|
InSys Therapeutics did not respond to a voice message left by VICE News.
|
|
Nektar Therapeutics was up 12%, on pace for its best day in a year.
|
|
Exonics Therapeutics develops gene editing therapies to treat patients with severe genetic neuromuscular diseases.
|
|
NEW YORK (Reuters) - A former chief financial officer of biotechnology company Osiris Therapeutics OSIR.
|
|
Sarepta Therapeutics shares soared Monday after the stock was upgraded to "outperform" at Oppenheimer.
|
|
" Insys Therapeutics: "This is a roll of the dice, 61 percent down, cancer therapeutic.
|
|
Decibel Therapeutics was incubated by the powerhouse investment firm and incubator Third Rock Ventures.
|
|
"The important thing is to start building an arsenal of other therapeutics," Kadouri said.
|
|
Intact Therapeutics: The makers of smart gels for local drug delivery for gastrointestinal diseases.
|
|
Former executives from Insys Therapeutics were recently found guilty of opioid-related bribery charges.
|
|
" Crispr Therapeutics AG: "The short term: it seems to be under pressure a lot.
|
|
Shouldn't companies making drugs, medical devices and therapeutics also have skin in the game?
|
|
Viosera Therapeutics: Uses AI to predict and block drug resistance in cancer and bacteria.
|
|
Nektar Therapeutics — The biopharmaceutical fell nearly 21.645 percent Friday after reporting fourth-quarter earnings.
|
|
One company, Insys Therapeutics, accounted for half of these payments, according to the study.
|
|
Aria, NuvoAir's digital therapeutics software, sends a patient personalized care suggestions based their condition.
|
|
Tell me about the biotech companies you co-founded, Crispr Therapeutics and ERS Genomics.
|
|
The Boston-based therapeutics company is focused on creating treatments for inner-ear disorders.
|
|
Such therapies for hemophilia are in development at drugmakers BioMarin, Spark Therapeutics and UniQure.
|
|
And in July, the company started working with biotech giant Genentech to develop therapeutics.
|
|
Their paper, published in the journal CNS Neuroscience and Therapeutics, doesn't mention head transplantation.
|
|
Cover: Insys Therapeutics founder John Kapoor, center, departs federal court in Boston, Wednesday, Jan.
|
|
CO) said on Tuesday the chief executive of Canadian biotech company Novelion Therapeutics (NVLN.
|
|
Most recently, Pain Therapeutics' abuse-deterrent opioid treatment was rejected for the fourth time.
|
|
Examples include Actiq and Fentora, made by Cephalon, and Subsys, made by Insys Therapeutics.
|
|
Aimmune Therapeutics (AIMT) received FDA approval for the first-ever treatment for peanut allergies.
|
|
The bride's father is the associate director of quality at Magenta Therapeutics in Cambridge.
|
|
"What is killing patients is limited oxygen delivery," said Dr. Love, of Global Therapeutics.
|
|
The groom, 36, is a principal associate scientist at Sigilon Therapeutics in Cambridge, Mass.
|
|
Alberta-based Aurora is also trying to buy fellow medical marijuana firm CanniMed Therapeutics.
|
|
TeGenero Immuno Therapeutics designed a drug to stimulate the immune system to fight leukemia.
|
|
Karuna Therapeutics took the top spot with a roughly 380% gain year to date.
|
|
Insys Therapeutics Inc filed for bankruptcy in June, also citing litigation over the epidemic.
|
|
Rivals such as Mirati Therapeutics Inc are also developing drugs that target KRAS mutations.
|
|
Krainc is a co-founder of Lysosomal Therapeutics and chairs its scientific advisory board.
|
|
United Therapeutics has settled the biggest claim, worth $210m, with the Department of Justice.
|
|
To act as its strategic financial advisor for review process * Nivalis Therapeutics - intends to complete its ongoing SNO-7 trial of cavosonstat in patients with cf who are currently taking kalydeco (ivacaftor) * Nivalis Therapeutics - to explore and review a range of strategic alternatives to maximize stockholder value from clinical assets and cash resources * Nivalis Therapeutics - potential strategic alternatives that may be explored include acquisition, merger, business combination other strategic deals * Nivalis Therapeutics Inc - ongoing SNO-7 trial of cavosonstat in patients with cf is expected to be completed in Q1 of 2017 Source text for Eikon: Further company coverage:
|
|
Antera Therapeutics is a pricey way to introduce peanuts Antera Therapeutics is a Boston-based biomedical startup led by a former Pfizer biochemist, funded by Big Pharma alumni, and linked with Harvard's iLab incubator, and it has the hallmarks of a sterling upstart.
|
|
Investments included a $175 million deal with CRISPR Therapeutics — a genetic therapeutics company that uses the cut-and-paste CRISPR/Cas9technique of genetic editing to pursue new, innovative treatment for muscular dystrophy — and a $245 million acquisition of gene-editing company Exonics.
|
|
To start, Regeneron is working with companies like gene-editing biotech Intellia Therapeutics and hearing-loss biotech Decibel Therapeutics to develop treatments as well as working with companies trying to infect cancer tumors with viruses that fight cancer, known as oncolytic viruses.
|
|
They are pulled from a basket of Russell 3000 stocks that were ranked based on their cheapness and upside to JPMorgan&aposs price targets:Mylan, Allscripts Healthcare Solutions, Universal Health Services, HCA Healthcare, Cardinal Health, United Therapeutics, Nektar Therapeutics, Perrigo, Centene, and Mednax.
|
|
Echo Therapeutics, that broadly defined the scope of official actions by corporate officers and directors.
|
|
She receives funding from Action on Hearing Loss, British Tinnitus Association, Autifony Therapeutics and MRC.
|
|
SPR Therapeutics will make its SPRINT device, the one Dean tried, available early this year.
|
|
Another San Francisco-based start-up, Lief Therapeutics, has a biosensing patch that relieves stress.
|
|
It now bills its technology as a "pediatric behavioral health diagnostics and digital therapeutics platform".
|
|
In our view, the time is right to invest in mental health and digital therapeutics.
|
|
February 6: Rapt Therapeutics (US, biotech) – $2100m FO. 214m shares (216% prim) versus $213 launch.
|
|
February 6: Rapt Therapeutics (US, biotech) – $17.43m FO. 2m shares (100% prim) versus $42.36 launch.
|
|
Axios spoke to Crowley, currently chairman and CEO of publicly-traded Amicus Therapeutics, via phone.
|
|
This is not about therapeutics or repair, but about augmenting human senses beyond the norm.
|
|
Spark Therapeutics – Spark and Swiss drugmaker Roche have hit another delay in their planned combination.
|
|
SyntheX Labs– SyntheX uses synthetic lethality to create peptide therapeutics that can treat incurable cancers.
|
|
One case of this happened recently with Juno Therapeutics, another leading player for cancer immunotherapy.
|
|
That is the strategy employed by C3J Therapeutics, in Marina del Rey, near Los Angeles.
|
|
Nektar Therapeutics and Newell Brands are also among the S&P 500's worst performers.
|
|
Leading the Russell higher on Friday were shares of PTC Therapeutics, which soared 88.3 percent.
|
|
United Therapeutics created a subsidiary for its organ effort called Lung Biotechnology Public Benefit Corp.
|
|
Advances in diagnostics, vaccines, and therapeutics hold great promise in preventing and responding to epidemics.
|
|
In March, Smith & Nephew bought U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million.
|
|
" Nektar Therapeutics: "I can't say it's in the lead [for developing non-addictive opioid treatments].
|
|
For their third and final pick, Stevens Institute Investment Club chose pharmaceutical company SAGE Therapeutics.
|
|
Details of the procedures are set to appear the journals Surgery and CNS Neuroscience & Therapeutics.
|
|
Express Scripts, Humana, MedImpact, Optum RX and Prime Therapeutics all wrote in letters to Sens.
|
|
The other day we saw another company, Revance [Therapeutics], have a competitive product to Botox.
|
|
Our company, Lakewood-Amedex, for instance, generates targeted therapeutics that silence or regulate gene expression.
|
|
But with its newest drug, biotechnology company Aimmune Therapeutics is trying to buck the trend.
|
|
Over the weekend, PTC Therapeutics presented promising research at the CureSMA researcher conference in Dallas.
|
|
Kite Pharma rose 290 percent to $229 while Juno Therapeutics gained 10.5 percent to $48.50.
|
|
Opportunities: healthcare, therapy Another non-obvious upside of VR will be VR-enabled digital therapeutics.
|
|
Several of the authors are employees of Astraea Therapeutics, which is developing the potential drug.
|
|
A company called Juno Therapeutics was spun out of Fred Hutch to work on this.
|
|
" Aimmune Therapeutics: "I think it's a very good spec ..." Telenav: "I don't know that one.
|
|
O), which began enrolling patients in clinical trial in July, and Sangamo Therapeutics Inc (SGMO.
|
|
The groom, 23, is the manager of business development at Pandion Therapeutics in Cambridge, Mass.
|
|
Liu's base editing company, Beam Therapeutics, has also been granted a sublicense for certain fields.
|
|
WHO SAYS EXPECTS RESULTS IN THREE WEEKS ON TWO TRIALS OF THERAPEUTICS FOR CORONAVIRUS INFECTIONS
|
|
ADC Therapeutics SA, a biotechnology company, abandoned its IPO last week, citing adverse market conditions.
|
|
"When we were dealing with SARS, we developed monoclonal antibodies as potential therapeutics," Fauci said.
|
|
Shares of Insys Therapeutics fell 6 percent in extended trading after a disappointing earnings report.
|
|
Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Ember Therapeutics' business and Ember Therapeutics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
|
|
Issues statement regarding department of justice press release * Insys Therapeutics Inc - "charges against individuals discussed in doj press release relate to previously disclosed investigations" * Insys Therapeutics Inc - continues to cooperate with all relevant authorities in its ongoing investigations Source text for Eikon: Further company coverage:
|
|
Celldex Therapeutics Inc: * CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND YEAR END 2019 RESULTS * CELLDEX THERAPEUTICS - BELIEVES CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AT DEC 31, 2019 SUFFICIENT TO FUND PLANNED OPERATIONS INTO Q1 2021 Source text for Eikon: Further company coverage:
|
|
The firm&aposs biggest fund lost more than 9% in August, but still rallied to beat the market and the average hedge fund, thanks to the performance of some of the biotech-focused fund&aposs biggest names, like Global Blood Therapeutics and Mirati Therapeutics.
|
|
One such startup, Denali Therapeutics, which he helped found, focuses on Alzheimer's and other neurodegenerative diseases.
|
|
Privately held SPR Therapeutics told Reuters it has entered its "temporary" neuromodulation device in the contest.
|
|
Insys Therapeutics is the maker of Subsys, a version of the extremely powerful synthetic opioid fentanyl.
|
|
Aimmune Therapeutics, a California-based biotech company that develops treatments for food allergies, is worse off.
|
|
February 17.43: Revance Therapeutics (US, biotech) – $200m 7y cvt talked at 1.75%-2150%, up 2100%-230.58%.
|
|
IN THE pharma business, Juno Therapeutics, a small firm based in Seattle, is just a stripling.
|
|
He and his colleagues started a company called Falcon Therapeutics to drive this new therapy forward.
|
|
It's worth noting that several Blue Cross Blue Shield companies also own a PBM, Prime Therapeutics.
|
|
That is until she sees the words "integrated therapeutics" written at the entrance of a hallway.
|
|
The treatment, developed by Philadelphia-based Spark Therapeutics Inc, is expected to be priced at $850,000.
|
|
" Sarepta Therapeutics: "I think that trade has come and gone and you should ring the register.
|
|
Aimmune Therapeutics Inc said on Monday that review of its peanut allergy treatment was being delayed.
|
|
Drug maker Juno Therapeutics is another; it is now getting acquired for $9 billion by Celgene.
|
|
Merck (NYSE: MRK) agreed to buy Peloton Therapeutics, a Dallas-based developer of oral oncology drugs.
|
|
But two other prominent pot stocks, GW Pharmaceuticals and Cara Therapeutics, have shrugged off the news.
|
|
Sage Therapeutics has said the infusion will cost around $34,000 per patient, before discounts are applied.
|
|
Sarepta Therapeutics rose 4.8 percent to $51.30 after Cowen & Co upgraded the drugmaker's stock to "outperform".
|
|
Amicus Therapeutics shares have risen slightly more than 1 percent since the beginning of the year.
|
|
S) Health Science unit will invest $145 million in U.S. food allergy specialist Aimmune Therapeutics (AIMT.
|
|
The Texas-based manufacturer behind the drug, Neos Therapeutics, specializes in developing drugs specifically for ADHD.
|
|
Jonathan Roper, once a sales manager at Insys Therapeutics, a small pharmaceutical company, had a problem.
|
|
Yusuf Sherwani is CEO at Digital Therapeutics and a senior medical student at Imperial College London.
|
|
GlaxoSmithKline (GSK) is shedding its rare disease gene therapy drug portfolio to privately-held Orchard Therapeutics.
|
|
And Celgene's purchase of Juno Therapeutics for $9 billion last year didn't work out as planned.
|
|
Voretigene neparvovec, which will be sold as Luxturna, is made by Philadelphia-based Spark Therapeutics Inc.
|
|
Stemline Therapeutics shares dropped as much as 9.9 percent to $7.82, before partially recovering to $8.5.
|
|
One of those specialized companies, Juno Therapeutics, has a market value almost as high as Intrexon's.
|
|
CONSENTS TO POSTPONEMENT OF CANNIMED THERAPEUTICS' SPECIAL SHAREHOLDERS' MEETING Source text for Eikon: Further company coverage:
|
|
Sarepta Therapeutics rose nearly 5 percent after Janney raised its price target by $5 to $30.
|
|
What they're saying: The results are "plausible," the CEO of CRISPR Therapeutics, Sam Kulkarni, told STAT.
|
|
Leslie Busby, MD is chairman of The US Oncology Network's Pharmacy and Therapeutics (P&T) Committee.
|
|
Sage Therapeutics has got a competitive drug to something that they may be doing for depression.
|
|
Allergan, the maker of Botox, announced yet another acquisition as it agreed to buy Tobira Therapeutics.
|
|
Tobira Therapeutics stock vaulted more than 700 percent after Allergan agreed to buy the drug developer.
|
|
Stermina Therapeutics This is another mRNA vaccine project, based at Shanghai East Hospital of Tongji University.
|
|
We need to launch two task forces dedicated to development of therapeutics and vaccines inside FDA.
|
|
We recommend that therapeutics be tested under ethically approved clinical trials to show efficacy and safety.
|
|
Besides suing Purdue Pharma, the Christie administration also sued Insys Therapeutics, an Arizona-based opioid manufacturer.
|
|
Aimmune Therapeutics designed and sponsored the clinical trial, which was carried out at multiple medical centers.
|
|
Three years ago, he started his own drug company, Finch Therapeutics, which has raised $77 million.
|
|
One priority is to make sure that there is enough manufacturing capacity for therapeutics and vaccines.
|
|
In partnership with United Therapeutics, the group has already built a farm for gene-edited pigs.
|
|
Gurry is one of five employees of Insys Therapeutics convicted of racketeering conspiracy in the scheme.
|
|
Celgene is buying the rest of Juno Therapeutics that it doesn't already own for $9 billion.
|
|
Sarepta Therapeutics (SRPT) received an early FDA approval for its second treatment for Duchenne muscular dystrophy.
|
|
To DynamiCare Health, Biobot Analytics and Pear Therapeutics, for using tech to address the opioid crisis.
|
|
January 62.5: Denali Therapeutics (US, biotech) – $2151.2m FO. Fixed size (21100% prim) versus $2117 at launch.
|
|
Sarepta Therapeutics – The drugmaker announced positive study results for a new treatment for Duchenne Muscular Dystrophy.
|
|
January 23: Applied Therapeutics (US, biotech) – $85m FO. 305.93m shares (100% prim) versus $48.35 at launch.
|
|
Currently, digital therapeutics are being developed to help treat insomnia, opioid dependence, chronic disease and more.
|
|
Chris Collins, who represents a Buffalo-area district, had been touting Innate Therapeutics' prospects for years.
|
|
Read more about the possible deal between Celgene and Juno Therapeutics from The Wall Street Journal.
|
|
The furthest along of these drug candidates is Palforzia, developed by the California-based Aimmune Therapeutics.
|
|
A takeover of Spark Therapeutics (ONCE) by Swiss drugmaker Roche has won clearance from British regulators.
|
|
Hours later, cancer drugmaker Celgene announced a deal for its partner, Juno Therapeutics, for $9 billion.
|
|
BAML, BTG, JPM, ITAU, CS, BRAD, SANT, BB. September 251.00: Nightstar Therapeutics (UK, biotech) – $80.4m IPO.
|
|
Protagonist Therapeutics wants to change that, instead of using the same approach but in a pill.
|
|
Fda that its clinical trials for selinexor have been placed on partial clinical hold * Karyopharm Therapeutics- fda has indicated partial clinical hold is due to incomplete information in existing version of investigator's brochure * Karyopharm Therapeutics - partial clinical hold is not result of any patient death or any new information regarding safety profile of selinexor * Karyopharm Therapeutics inc - as of march 10, co had provided all requested materials to fda believed to be required to lift partial clinical hold * Karyopharm Therapeutics says co believes its previously disclosed enrollment rates and timelines for its ongoing trials will remain materially unchanged Source text for Eikon: Further company coverage:
|
|
The start-up, which launched in September and is headquartered in Warren, N.J., announced Thursday it has raised $240.7 million in venture capital from global biopharmaceutical company Celgene, biotechnology company United Therapeutics Corporation, biopharmaceutical company Sorrento Therapeutics, DNA sequencing and machine learning company Human Longevity, Inc.
|
|
Nektar Therapeutics shares plunged after the drug developer flagged manufacturing issues with its experimental cancer drug bempeg.
|
|
Medical cannabis may just be one of those therapeutics that triggers a different response according to sex.
|
|
The drug regulator on Friday also approved a treatment from Stemline Therapeutics for another rare blood disorder.
|
|
Edelman remains bullish on Sarepta Therapeutics and believes its Duchenne muscular dystrophy drug, eteplirsen, will be approved.
|
|
Revenue also beat Wall Street forecasts, helped by better-than-expected specialized therapeutics and general medicine sales.
|
|
The company also has a business arm devoted to developing therapeutics based on the information it collects.
|
|
The Company operates in one reportable segment, which comprises the discovery and development of innovative bispecific therapeutics.
|
|
And experts thought Hiroshi Maeda and Yasuhiro Matsumura could win for a key finding for cancer therapeutics.
|
|
Bio-therapeutics company CSL Ltd was the biggest boost to the main index and rose 1.2 percent.
|
|
I want to get back to therapeutics, but a lot of Silicon Valley people are doing this.
|
|
And viruses modified to deliver genetic therapeutics are currently yielding increasing cure rates in previously deadly cancers.
|
|
Roche, the Swiss-based pharmaceutical conglomerate, is acquiring Spark Therapeutics in a $4.8 billion all-cash deal.
|
|
On Tuesday, the FDA approved Sage Therapeutics' Zulresso for the treatment of postpartum depression in adult women.
|
|
In May, he and Zhang launched Beam Therapeutics, to turn base editing into treatments for genetic diseases.
|
|
The NIH's partner, Moderna Therapeutics, says it could produce up to 100 million doses of a vaccine.
|
|
Shares of Nektar Therapeutics and HCA Healthcare dragged down the sector, falling more than 27.5 percent each.
|
|
PM remains part of the solution, but it must catch up with our understanding of cancer therapeutics.
|
|
Clover Therapeutics also announced an initial research partnership and license agreement with Roche-owned biotech company Genentech.
|
|
Shares of other companies developing gene therapies, including Solid Biosciences and Spark Therapeutics, also surged on Tuesday.
|
|
ZURICH, Oct 29 (Reuters) - Roche said it extended its tender offer for shares of Spark Therapeutics, Inc.
|
|
The company said the new generic will be available through its subsidiary, IJ Therapeutics, in mid-2019.
|
|
Cameron Turtle is the 29-year-old chief business officer of the rare-disease biotech Eidos Therapeutics.
|
|
Biotechnology company Gilead Sciences works in discovering, developing and commercializing therapeutics that help patients improve their health.
|
|
Reset Therapeutics is now halfway through stage one of clinical testing to determine drug safety in humans.
|
|
Recently Juno Therapeutics had to temporarily halt its clinical trial after three patients died from brain swelling.
|
|
Esperion Therapeutics jumped 553 percent to $47.48 after J.P. Morgan raised its price target on the stock.
|
|
Pfizer is racing Sarepta Therapeutics Inc to be first to market with a gene therapy for DMD.
|
|
That may seem a long way off, but it's actually a speedy timeline by therapeutics development standards.
|
|
The infusion will be expensive, averaging $34,000 per patient before discounts, according to Sage Therapeutics, the manufacturer.
|
|
The COVID-19 Therapeutics Accelerator will also be working with the World Health Organization on the project.
|
|
A small group of post-surgery pain drug makers, including Heron Therapeutics, stand to benefit from Rep.
|
|
For now, the company that sells the drug, Sarepta Therapeutics, is covering the treatment's costs, but Mrs.
|
|
Nektar Therapeutics — The biopharma stock gained more than 8% after Mizuho upgraded Nektar to a buy rating.
|
|
Spark Therapeutics, a gene therapy company, hired Jeremy Allen to serve as the head of government relations.
|
|
Shares of NewLink Genetics Corp tumbled 39 percent, while those of Nektar Therapeutics were down 8 percent.
|
|
" Halozyme Therapeutics and Kratos Defense & Security Solutions: "You've got Lockheed Martin, you've got Raytheon down big today.
|
|
That was a pivotal finding, said Dr. Robert Conley, global development leader for migraine therapeutics at Lilly.
|
|
And that has now been dubbed Digital Therapeutics — DTx — is the common term being used for them.
|
|
CS. January 203: Applied Therapeutics (US, biotech) – $105m FO. 2.25m shares (100% prim) versus $48.35 at launch.
|
|
Nektar Therapeutics (NKTR) withdrew its application for its opioid painkiller designed to treat chronic low back pain.
|
|
The Swiss drugmaker again extended its offer for shares of gene therapy specialist Spark Therapeutics to Dec.
|
|
Spark Therapeutics (ONCE) – A takeover of Spark by Swiss drugmaker Roche has won clearance from British regulators.
|
|
Pain Therapeutics is not the first drugmaker whose reformulated version to deter abuse has hit a roadblock.
|
|
U.S. JUDGE PARTIALLY OVERTURNS CONVICTION OF INSYS THERAPEUTICS INC FOUNDER JOHN KAPOOR, DENIES REQUEST FOR NEW TRIAL
|
|
The top-performing hedge funds added positions in Sarepta Therapeutics and Tempur Sealy in the June quarter.
|
|
February 11 (PM): Revance Therapeutics (US, biotech) – $200m 7y cvt talked at 1.75%-2.25%, up 27.5%-32.5%.
|
|
We identified at least seven companies in the space — Tmunity Therapeutics, Neon Therapeutics, Gritstone Oncology, Forty Seven, Arcus Biosciences and FLX Bio — that have raised $100 million or more in less than three years (another, Celularity is focused broadly on placental stem cell therapies, with some immuno-oncology applications).
|
|
In 2014, the drugmaker entered into a collaboration with Philadelphia-based Spark Therapeutics Inc to develop SPK-9001, a gene therapy for hemophilia B. Earlier this year, Pfizer signed a collaboration and license agreement with Emeryville, California-based 4D Molecular Therapeutics to develop targeted vectors for cardiac disease.
|
|
This month, biotech firm CRISPR Therapeutics became the first to submit a clinical trial application to European regulators.
|
|
Nektar Therapeutics shares plunged 32.9% after the drug developer flagged manufacturing issues with its experimental cancer drug bempeg.
|
|
Grubhub, Nektar Therapeutics and bluebird bio are among the companies expected to be added to the largecap index.
|
|
Sage Therapeutics shares soared after the company reported positive late-stage data on its treatment for postpartum depression.
|
|
Nektar Therapeutics shares plunged 36% after the drug developer flagged manufacturing issues with its experimental cancer drug bempeg.
|
|
And other companies such as Accorda Therapeutics, Acella Pharmaceuticals, and Intercept announced price increases this month as well.
|
|
At the time, Colman was research director at PPL Therapeutics, which specialized in producing transgenic (genetically engineered) livestock.
|
|
Kavanaugh in 2013 also sided with the FDA in a case against Cytori Therapeutics, a medical device maker.
|
|
Nektar Therapeutics shares plunged 34.1% after the drug developer flagged manufacturing issues with its experimental cancer drug bempeg.
|
|
Moderna Therapeutics went public in the largest biotech offering ever earlier this month, raising more than $600 million.
|
|
VERDICT REACHED IN U.S. TRIAL OF FIVE FORMER EXECUTIVES OF INSYS THERAPEUTICS ACCUSED OF OPIOID BRIBE SCHEME -PROSECUTORS
|
|
In addition to Solid Biosciences, there has been work by both Sarepta Therapeutics (Nasdaq: SRPT) and Marathon Pharma.
|
|
Sarepta Therapeutics, the firm behind the drug, did not meet the usual standards for approval to market it.
|
|
TG Therapeutics is unlike most small biotech companies that go after niche markets, CEO Michael Weiss told Cramer.
|
|
Along with other biotech stocks, United Therapeutics has had a tough year, down nearly 30 percent in 2016.
|
|
Insys Therapeutics — Shares of the pharmaceutical company dropped 4.4% after announcing CEO Saeed Motahari will leave his post.
|
|
Allogene Therapeutics, a clinical-stage biotech company developing new therapies for cancer, debuted on the public markets Thursday.
|
|
What CB Therapeutics has done is bioengineer microorganisms — specifically yeast — to manufacture cannabinoids out of plain-old sugars.
|
|
This is, of course, particularly true in the U.K. Against this backdrop, digital therapeutics are a great solution.
|
|
However in August, Walgreens announced it would partner with Prime Therapeutics to better compete with companies like CVS.
|
|
This may be the last networking deal we do, or the last targeted therapeutics deal we ever do.
|
|
Founder Jessica Richman now says there's a wider opportunity to use this data to create value in therapeutics.
|
|
But the antics of Insys Therapeutics, now being revealed in an ongoing federal court battle, seem especially evil.
|
|
The venture firm invests in start-ups in the diagnostics, therapeutics, research and development and clinical care fields.
|
|
Nektar Therapeutics shares plunged 38.2% after the drug developer flagged manufacturing issues with its experimental cancer drug bempeg.
|
|
Nektar Therapeutics shares plunged 33.1% after the drug developer flagged manufacturing issues with its experimental cancer drug bempeg.
|
|
Shares of Insys Therapeutics dropped about 8 percent Monday amid renewed concerns over the pharmaceutical company's sales practices.
|
|
But, there's a redeemable quality about this particular fund, which counts Illumina and Crispr Therapeutics in its holdings.
|
|
Acorda Therapeutics – The drugmaker reported significantly positive results in a trial involving a new drug for Parkinson's disease.
|
|
TC: One of your portfolio companies is Unity Biotechnology, a company that's trying to reverse aging through therapeutics.
|
|
" Celldex Therapeutics: "I have it down a huge number of points, the stock just rallied a little bit.
|
|
Juno Therapeutics sank 14 percent after reporting that two patients died during a trial of its leukemia drug.
|
|
He said he is studying variations of that approach with French drugmaker Cerenis Therapeutics and the Medicines Company.
|
|
Refinery29 has reached out to Sage Therapeutics for comment, and will update this story if we hear back.
|
|
Crispr Therapeutics is working first on cystic fibrosis and sickle cell disease, and certain types of eye disease.
|
|
Round size and year: $250 million in 2018More about Celularity:, Investors include United Therapeutics, Human Longevity and Celgene.
|
|
The approval delighted the drug's advocates and sent the share price of the drug's maker, Sarepta Therapeutics, soaring.
|
|
Seth Yakatan, CEO of California-based Kalytera Therapeutics, said the level of capital efficiency in Israel was high.
|
|
In contrast, the best performing stock this year in the Nasdaq Composite, Sangamo Therapeutics, is up 324 percent.
|
|
NEW YORK (Reuters) - Last August, National Securities Corp analyst Jonathan Aschoff was bullish on Avenue Therapeutics Inc (ATXI.
|
|
Former CEO Michael Babich and six other executives of Insys Therapeutics were charged with conspiracy to commit racketeering.
|
|
Juno Therapeutics Inc scrapped its initial CAR-T candidate for acute lymphoblastic leukemia (ALL) after five patient deaths.
|
|
Moreover, they will continue to perform sophisticated surgery, diagnostics and therapeutics at the cutting edge of scientific development.
|
|
In bidding that closed on Thursday, Louisiana received responses from AbbVie, Merck and a Gilead subsidiary, Asegua Therapeutics.
|
|
Deals • Moderna Therapeutics, a biotech start-up currently valued at $7.5 billion, is reportedly preparing to go public.
|
|
A good example is the need to test therapeutics wherever the disease is to help the whole world.
|
|
For us, that falls into two tracks one of them you mentioned, which is the AbCellera therapeutics collaboration.
|
|
Another motivation to develop better blood tests is the potential to develop therapeutics from antibody-rich blood serum.
|
|
The goal: to discover and develop new protein therapeutics that are currently hard for humans alone to find.
|
|
United Therapeutics Corp in July said it set aside $210 million to resolve claims arising from the probe.
|
|
During five years of follow-up, 7,488 people died of cancer, researchers report in Alimentary Pharmacology and Therapeutics.
|
|
Drivers of operational improvement that would support a positive revision include strong demand for newer, patent-protected therapeutics.
|
|
Nektar Therapeutics (NKTR) – Nektar withdrew its application for its opioid painkiller designed to treat chronic low back pain.
|
|
One of the biggest developers of antibiotics, Melinta Therapeutics, recently warned regulators it was running out of cash.
|
|
The trial, from Aimmune Therapeutics, involves eating a carefully formulated amount of a peanut protein powder each day.
|
|
The Johnson-led venture arm scored another big payday when Adaptimmune Therapeutics plc went public in May 2015.
|
|
"The reputational aspects of the industry are not on Jim's shoulders," said Levin, the CEO of Ovid Therapeutics.
|
|
Acorda Therapeutics – The drugmaker has reportedly received takeover interest from biotech firm Biogen, according to a Bloomberg report.
|
|
Aimmune Therapeutics – A Food and Drug Administration panel recommended approval of Aimmune's treatment for peanut allergies in children.
|
|
The Plasma Protein Therapeutics Association, a trade group, disputes the idea that the industry depends on desperate people.
|
|
Bayer and Vertex Pharmaceuticals have independently established collaborations with CRISPR Therapeutics, a biotech firm working on gene therapies.
|
|
Amends genuine phase 3 clinical trial to accelerate study completion by revising primary endpoint to overall response rate * TG Therapeutics Inc- enrollment expected to be completed before year end 2016 with top-line data available in first half of 2017 * TG Therapeutics - if results of revised genuine study are positive, plans to file a bla for accelerated approval based on outcome of pre-BLA meeting * FDA agrees that overall response rate (orr) data from revised genuine study can be used to request pre-BLA meeting * TG Therapeutics - amendments expected to save co more than $10 million over next 2 years, and allow company to focus its resources on unity-CLL program * TG Therapeutics Inc- company believes it could file a BLA in first half of 2018 * TG Therapeutics Inc - target enrollment for genuine phase 3 trial has been reduced to approximately 120 randomized patients Source text for Eikon: Further company coverage:
|
|
PLACEBO OBSERVED IN 3-MONTH POST-TREATMENT FOLLOW-UP EVALUATION IN TRIAL * ACLARIS THERAPEUTICS INC - THERE WERE NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS AMONG SUBJECTS TREATED WITH A-101 45% * ACLARIS THERAPEUTICS INC - A-101 45% WAS GENERALLY WELL TOLERATED THROUGH VISIT 13 Source text for Eikon: Further company coverage:
|
|
Board of Directors ■ Aura Biosciences* (cancer startup) ■ Bristol-Myers Squibb ■ Foghorn Therapeutics (cancer startup) ■ Grail* (cancer testing startup) ■ Infinity Pharmaceuticals* (cancer startup) ■ Varian Medical Systems (radiation equipment) Scientific or Clinical Advisory Board ■ ApoGen Biotechnologies (cancer startup) ■ Aura Biosciences (cancer startup) ■ Grail (cancer testing startup) ■ Juno Therapeutics* ■ Northern Biologics (cancer startup) ■ Paige.
|
|
Importantly, these insights could inspire the development of novel therapeutics to treat conditions such as anxiety and chronic headaches.
|
|
Sarepta Therapeutics jumped 21.2 percent to $22.46 after the FDA delayed its decision on the company's muscle-wasting drug.
|
|
The four winners of ASCO that Cramer highlighted were Bristol-Myers Squibbs, Eli Lilly, Johnson & Johnson and Juno Therapeutics.
|
|
It was with Spark Therapeutics, a young biotech company formed out of research from the Children's Hospital of Philadelphia.
|
|
Juno Therapeutics rose about 27 percent after Celgene agreed to buy the biotech for about $9 billion in cash.
|
|
The Amazon CEO placed his bets on Juno Therapeutics back in 2014, through his venture capital arm Bezos Expeditions.
|
|
Merus N.V. is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, headquartered in Utrecht, the Netherlands.
|
|
"A master global clinical trial protocol for research and prioritization of therapeutics is ongoing at the WHO," it added.
|
|
In a 2011 review, Dan Roden, a experimental therapeutics researcher at Vanderbilt University, termed this the genotype–phenotype dilemma.
|
|
Juno Therapeutics sank 24.8 percent after it said two patients died during a trial of its experimental leukemia drug.
|
|
Rapt Therapeutics (US, biotech) – $75m FO. 2.5m shares (100% prim) at $30.00 versus $32.00 last sale and $1003 launch.
|
|
Rapt Therapeutics (US, biotech) – $75m FO. 2.5m shares (100% prim) at $30.00 versus $32.00 last sale and $42.36 launch.
|
|
Juno Therapeutics, another biopharmaceutical company developing immunotherapies, also saw its stock jump after the Kite Pharma news was released.
|
|
Juno Therapeutics, which also develops immunotherapies, saw its stock grow 9 percent in sympathy with the Kite Pharma news.
|
|
In corporate news, Juno Therapeutics shares plunged around 221.90 percent after the firm announced complications with a drug trial.
|
|
SAGE Therapeutics — the biopharmaceutical firm said it has begun a public offering of $150 million of its common stock.
|
|
" Sage Therapeutics: "Typically these secondaries have worked very well in this industry, and it did get the breakthrough designation.
|
|
Chaser: Just to give Khosrowshahi some antacid, both Zoom and Turning Point Therapeutics this morning increased their IPO size.
|
|
However, helped by the evidence that they work, the NHS is "learning" how to purchase and prescribe digital therapeutics.
|
|
Google co-founder Page announced the creation of Calico in 2013, a company focused on aging research and therapeutics.
|
|
Allergy Therapeutics, which specializes in allergy vaccines, said it now expected to enter the U.S. market later than expected.
|
|
Separately, Merck announced the acquisition of cancer drugmaker Peloton Therapeutics for $1.05 billion in cash plus possible milestone payments.
|
|
Juno Therapeutics is just one publicly traded company with a focus on cancer drugs targeted to unique DNA markers.
|
|
Aegerion, a Novelion Therapeutics Inc unit, agreed to pay $40.1 million to resolve probes into its promotion of Juxtapid.
|
|
So back-burnering vaccine development in favor of therapeutics and drugs to treat chronic conditions is just good business.
|
|
The lawsuit also names a third defendant, Insys Therapeutics, which Bondi says "provided kickbacks" to doctors who prescribed opioids.
|
|
Juno Therapeutics rose about 2473 percent after Celgene agreed to buy the biotech for about $2247 billion in cash.
|
|
Novartis is competing with Kite Pharma Inc, Juno Therapeutics Inc and Bluebird Bio Inc in the emerging lucrative field.
|
|
Moderna Therapeutics has raised another $500 million, which values the biotechnology startup at about $7.5 billion, PitchBook first reported.
|
|
Sarepta Therapeutics jumped 523 percent to $22.87 after the FDA delayed its decision on the company's muscle-wasting drug.
|
|
GlaxoSmithKline – The British drug maker is shedding its rare disease gene therapy drug portfolio to privately held Orchard Therapeutics.
|
|
Gene therapy companies such as REGENXBIO and Abeona Therapeutics rallied more than 15 percent in reaction to the deal.
|
|
Shares of Juno Therapeutics, third in line with CAR-T therapies in development, soared on news of the deal.
|
|
PTC Therapeutics Inc's DMD drug, Translarna, won conditional European approval in 2014, to treat a different subset of patients.
|
|
OrbiMed led a $40 million investment in Restorbio, a Boston biotech firm developing therapeutics to treat age-related diseases.
|
|
Moderna Therapeutics is banking an additional $125 million in an expanded partnership with Merck around a personalized cancer vaccine.
|
|
Spero Therapeutics raised $77 million in its Nasdaq IPO Wednesday, selling 5.5 million shares at $14 apiece, Xconomy reported.
|
|
Those efforts include Celgene's purchase earlier this year of Juno Therapeutics and Impact Biomedicines, two developers of cancer treatments.
|
|
The pharmaceutical company, which is focused on developing therapeutics to alter the course of Alzheimer's disease, funded the research.
|
|
The health insurer Clover Health is partnering with Genentech to develop treatments for diseases through the startup's therapeutics arm.
|
|
YourChoice Therapeutics, a startup founded by researchers from the University of California, Berkeley, is working to develop the contraceptive.
|
|
PTC Therapeutics' experimental drug poses a serious threat to Spinraza, the first drug that was approved to treat SMA.
|
|
In September it spun out a six-person start-up called SpringWorks Therapeutics to focus on developing experimental drugs.
|
|
Several of the authors who are claiming success are employees of Astraea Therapeutics, which is developing the potential drug.
|
|
In April, GSK said it was divesting its rare disease gene therapy drugs to private biotech company Orchard Therapeutics.
|
|
Wednesday CRISPR Therapeutics (Switzerland, biotech) – $274m FO. 4.3m shares (100% prim) at $64.50 versus $67.42 and $18.203 at launch.
|
|
Karuna Therapeutics (US, biotech) – $250m FO. 2.6m shares (100% prim) at $96.00 versus $453 last sale and $108.95 launch.
|
|
B. finished his residency swiftly and dove headlong into translational research ("translating" insights from basic sciences into human therapeutics).
|
|
Novartis owns the rights to sell the one-time gene therapy developed by Spark Therapeutics outside the United States.
|
|
Novartis owns the rights to sell the one-time gene therapy developed by Spark Therapeutics outside the United States.
|
|
A new category of prescription medical treatments, what executives call digital therapeutics, comes in the form of mobile apps.
|
|
RBC, CS, DB. March 1003: Karyopharm Therapeutics (US, biotech) – $150m FO. Fixed size (100% prim) versus $27.27 at launch.
|
|
Several vaccines are being studied, but the one moving the fastest is produced by Moderna Therapeutics of Cambridge, Mass.
|
|
There is reason to believe that will change now, along with other therapeutics that have efficacy in the lab.
|
|
Karyopharm Therapeutics (US, biotech) – $150m FO. 163m shares (100% prim) at $24.00 versus $24.68 last sale and $27.27 launch.
|
|
Karyopharm Therapeutics (US, biotech) – $210.00m FO. 6.25m shares (100% prim) at $24.00 versus $24.68 last sale and $27.27 launch.
|
|
Aimmune Therapeutics (AIMT) – The drugmaker received Food and Drug Administration approval for the first-ever treatment for peanut allergies.
|
|
And for pharmaceutical companies, some of the technologies used in digital therapeutics might not feel comfortable either, he said.
|
|
There have been two exits so far (IPO for SpringWorks Therapeutics and sale of Impact Fitness to Morgan Stanley).
|
|
Mirati Therapeutics (US, biotech) – $25m FO. 215m shares (49.003% prim) at $249.00 versus $250.53 last sale and $250.04 launch.
|
|
Mirati Therapeutics (US, biotech) – $302.3m FO. 3.1m shares (100% prim) at $97.50 versus $98.44 last sale and $104.74 launch.
|
|
"I think it's rather aggressive," said Brent Zettl, the president and chief executive of CanniMed Therapeutics in Saskatoon, Saskatchewan.
|
|
There are currently no vaccines or therapeutics approved by the U.S. Food and Drug Administration to treat the virus.
|
|
Esperion Therapeutics just received its first US approval on Friday, clearing the way to launch its first heart drug.
|
|
Her stepfather, who is retired, was the president and chief executive of PeriCor Therapeutics, a biotech company in Manhattan.
|
|
Intellia Therapeutics (US, biotech) - $150m FO. 6.25m shares (100% prim) at $24.00 versus $25.47 last sale and $393 launch.
|
|
Intellia Therapeutics, a biotechnology company, also hired Crossroads Strategies to work on education and advocacy related to gene therapy.
|
|
RBC, CS, DB. March 3: Karyopharm Therapeutics (US, biotech) – $150m FO. Fixed size (100% prim) versus $27.27 at launch.
|
|
Karyopharm Therapeutics (US, biotech) – $150m FO. 6.25m shares (100% prim) at $24.00 versus $24.68 last sale and $27.27 launch.
|
|
Protagonist Therapeutics, a biotech company based in the Bay Area, is trying to develop pill versions of injected drugs.
|
|
E-Therapeutics has fallen 9.1% since June 3, IP Group is down 8.1% and NewRiver REIT is off 8%.
|
|
The program has proven popular; in 2015, drugmaker AbbVie purchased a priority review voucher from United Therapeutics for $350 million.
|
|
Aimmune Therapeutics, which makes the peanut powder known as AR101, paid for the study, which involved 551 adults and children.
|
|
AT-121 research, for instance, is being led and funded by Astraea Therapeutics, a boutique biotech firm based in California.
|
|
Shares of Sarepta Therapeutics pared losses during early afternoon trading Wednesday as Wall Street digested the biopharmaceutical company's updated guidance.
|
|
At the time, the company also launched a new therapeutics division, recruiting scientists from major drug development companies like Genentech.
|
|
"We hope to fulfill our obligation to patients by trying to develop as many promising therapeutics as possible," Liu says.
|
|
Meanwhile, one of the largest donors to the anti-pot campaign has been painkiller manufacturer Insys Therapeutics, which gave $500,000.
|
|
Revance Therapeutics (US, biotech) – $250m 7y cvt priced at 1.75%, up 32.5% versus talked of 1.75%-1003% and 27.5%-32.5%.
|
|
Nektar Therapeutics' share price shot up by 40% after a study found that its drug dampens associated feelings of euphoria.
|
|
Similarly, Roche, which makes a hemophilia treatment, is buying Spark Therapeutics, which is trying to make a cure for hemophilia.
|
|
Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.
|
|
Juno Therapeutics (JUNO) shares are under pressure after U.S. regulators put a trial of a Juno cancer drug on hold.
|
|
It's also the same genetics information used by 23andMe's year-old therapeutics team, headed by Richard Scheller, chief science officer.
|
|
" Today, Ramaswamy called Axovant's results "disappointing for our company but also for a therapeutics area that really needed a win.
|
|
Denali Therapeutics (US, biotech) – $180m FO. 7.8m shares (100% prim) at $23.00 versus $8.503 last sale and $27.98 at launch.
|
|
However, the World Health Organization played it down, saying "there are no known effective therapeutics against this 22020-nCoV (virus)".
|
|
The pharma company may sell it to Canadian drugmaker Knight Therapeutics, according to Reuters, citing people familiar with the matter.
|
|
It's unclear what will happen to Intellia Therapeutic and CRISPR Therapeutics, two companies that licensed CRISPR-Cas9 technology from Berkeley.
|
|
Global Blood Therapeutics (GBT) announced positive results in a late-stage clinical trial for its experimental sickle-cell disease treatment.
|
|
Sarepta Therapeutics skyrocketed 73 percent on Monday on the news that the FDA approved its treatment for Duchenne muscular dystrophy.
|
|
Berkeley licensed its patents Intellia, which Berkeley's Jennifer Doudna is also a founder of, as well as to CRISPR Therapeutics.
|
|
Sage Therapeutics, the company that developed the drug, confirmed to CNN that the infusion will cost between $20,000 and $30,000.
|
|
Newark, California-headquartered Revance Therapeutics is also developing a rival to Botox, which could have longer effect in treating wrinkles.
|
|
Last month, for instance, immunotherapy pioneer Juno Therapeutics sold to pharma giant Celgene in a deal valued at $9 billion.
|
|
" Aratana Therapeutics: "If we are going to do pets, the only one I want is IDEXX ... that's my pet play.
|
|
One such, Pear Therapeutics, has a pipeline of treatments at various stages of development, much like a conventional pharmaceutical firm.
|
|
In 2014, Hughes had her own healthy stem cells cultured at Celltex Therapeutics, a FDA-regulated biotechnology company in Houston.
|
|
Spark Therapeutics – The drugmaker agreed to be bought by Switzerland's Roche for $4.3 billion or $114.50 per share in cash.
|
|
Allergan has a strong long-term outlook across its four key therapeutics areas and a highly promising R&D pipeline.
|
|
Waltham also attracted Dragonfly Therapeutics Inc, which looked at more than 40 sites in Cambridge, where it started in 2015.
|
|
Take Juno Therapeutics, a publicly traded cancer immunology company that sold to pharma giant Celgene this year for $214 billion.
|
|
Indicated 20.1 percent higher The group said it was expanding its collaboration with Storm Therapeutics on its RNA epigenetics platform.
|
|
The March for Science in Boston counts biopharma companies Intellia Therapeutics, Tetraphase Pharmaceuticals and Warp Drive Bio among its sponsors.
|
|
Federal officials Thursday indicted John Kapoor, the 74-year-old billionaire founder and majority owner of drug company Insys Therapeutics.
|
|
"Our biggest focus today is a research platform; we use it to examine new therapeutics for serious diseases," Beck says.
|
|
Shares of Forward Pharma and Acorda Therapeutics dropped Friday afternoon, after documents revealed both firms lost separate drug patent lawsuits.
|
|
Spark Therapeutics shares more than doubled after Swiss drugmaker Roche Holding AG agreed to buy the company for $4.3 billion.
|
|
ET: Jon Hilsenrath, Wall Street Journal global economics editor; John Crowley, Amicus Therapeutics CEO; Trae Stephens, Anduril Industries chairman; Rep.
|
|
Eventually, some scientists believe, treatments for most cancers could come in the form of multiple advanced therapeutics, applied in parallel.
|
|
Gibson says other AI startups have also made real progress, pointing to Daphne Koller's Insitro, Nimbus Therapeutics, BenevolentAI and Atomwise.
|
|
Zulresso's manufacturer, Sage Therapeutics, has said a course of treatment for the drug would likely cost between $85033,000 and $35,000.
|
|
" Sarepta Therapeutics: "Sarepta is a tough situation because there were articles yesterday about a guy from the FDA who left.
|
|
Blackstone Life Sciences is contributing $250 million to the venture and will control the new company called Anthos Therapeutics. on.wsj.
|
|
Sage Therapeutics CEO Jeff Jonas hopes a drug in development for major depressive disorder will be as big as Prozac.
|
|
Abeona Therapeutics is taking gene therapy technology developed by researchers at Nationwide Children's Hospital in Columbus, Ohio to treat Sanfilippo.
|
|
Large pharmaceutical companies have increased investments in cancer-therapeutics startups, from $85033 billion in 2013 to $4.5 billion in 2017.
|
|
He declined to comment on whether Novartis had bid for U.S. group Spark Therapeutics, which Roche has agreed to buy.
|
|
Spark Therapeutics shares rose as much as 6.8 percent before turning negative and closing down 0.2 percent on the day.
|
|
Caribou's chief executive thinks of her company as a platform for developing technologies in therapeutics, research, agriculture and industrial biology.
|
|
Sarepta Therapeutics Inc is currently the market leader for DMD treatment after its drug won U.S approval two years ago.
|
|
CS, GS, BOFA, DB. November 20: Karuna Therapeutics (US, biotech) – $250m FO. 2.6m shares (10.003% prim) versus $96.00 at launch.
|
|
The start-up has since raised $70 million and licensed a variety of digital therapeutics from researchers and other companies.
|
|
In the age of molecular therapeutics, perhaps we might need to rethink diet, too, as a form of molecular therapy.
|
|
We have therapeutics being developed through a consortium of pharmaceutical companies that the president organized more than a month ago.
|
|
John P. Butler is the chair of Kidney Care Partners and president and Chief Executive Officer of Akebia Therapeutics, Inc.
|
|
Denali Therapeutics (US, biotech) – $180m FO. 7.83m shares (100% prim) at $1793 versus $1783 last sale and $1773 at launch.
|
|
Applied Therapeutics (US, biotech) – $21.24m FO. 295m shares (284% prim) at $216 versus $213.00 last sale and $214.40 at launch.
|
|
Meretzki previously founded Pluristem Therapeutics, which works with stem cells and is one of the more advanced Israeli biomed companies.
|
|
The FDA said late Thursday it approved Sarepta Therapeutics' Vyondys 53 for patients with a form of Duchenne's muscular dystrophy.
|
|
Denali Therapeutics (US, biotech) – $1753m FO. 1743m shares (1733% prim) at $1723 versus $1713 last sale and $1703 at launch.
|
|
"Whenever you meet a fundamental human need, there's a market," said Michael West, a gerontologist and CEO of AgeX Therapeutics.
|
|
Applied Therapeutics (US, biotech) – $124.7m FO. 2.7m shares (100% prim) at $15.993 versus $48.85 last sale and $48.35 at launch.
|
|
INSYS THERAPEUTICS FOUNDER JOHN KAPOOR SENTENCED TO 66 MONTHS IN PRISON FOR ROLE IN OPIOID FRAUD SCHEME - U.S. DISTRICT JUDGE
|
|
TORONTO (Reuters) - Ontario Securities Commission will hold hearings on Aurora Cannabis's hostile takeover bid for rival CanniMed Therapeutics on Dec.
|
|
They combine the stability benefits of small-molecule drugs, like aspirin, and the specificity of large antibody therapeutics, like herceptin.
|
|
Sage Therapeutics — Sage's stock plunged 60% after the company announced its oral depression therapy failed in a late-stage trial.
|
|
Horizon Therapeutics (HZNP) said an FDA advisory committee voted to recommend approval of a new treatment for thyroid eye disease.
|
|
With its suite of blood disease treatments under development, Global Blood Therapeutics would be a boon to Novo Nordisk's portfolio.
|
|
Revance Therapeutics (US, biotech) – $250m 7y cvt priced at 1.75%, up 32.5% versus talk of 1003%-2.25% and 27.5%-32.5%.
|
|
AI (pathology startup) ■ Peptomyc* (cancer startup) ■ PMV Pharmaceuticals (cancer startup) ■ Seragon Pharmaceuticals* (breast cancer) Founder or Co-Founder ■ Mosaic Biomedicals* ■ Tango Therapeutics (cancer startup) Paid Consultant ■ AstraZeneca* ■ Eli Lilly* ■ Novartis* ■ Roche/Genentech* Board of Directors ■ Aura Biosciences* (cancer startup) ■ Bristol-Myers Squibb ■ Foghorn Therapeutics (cancer startup) ■ Grail* (cancer testing startup) ■ Infinity Pharmaceuticals* (cancer startup) ■ Varian Medical Systems (radiation equipment) Paid Consultant ■ AstraZeneca* ■ Eli Lilly* ■ Novartis* ■ Roche/Genentech* Scientific or Clinical Advisory Board ■ ApoGen Biotechnologies (cancer startup) ■ Aura Biosciences (cancer startup) ■ Grail (cancer testing startup) ■ Juno Therapeutics* ■ Northern Biologics (cancer startup) ■ Paige.
|
|
Food and drug administration in its 2013 complete response letter to company * Says resubmission of twirla new drug application expected to address fda's complete response letter * Agile Therapeutics Inc - believes its cash and cash equivalents will be sufficient to meet its operating requirements through end of 2017 * Agile Therapeutics Inc - twirla was generally well tolerated and had an overall favorable safety profile * Agile Therapeutics - plans to prepare its response to fda's crl, which will also include information relating to manufacture of twirla requested by FDA Source text for Eikon: Further company coverage:
|
|
Bristol-Meyers is essentially banking on the success of Celgene's newly acquired drugs, like the cancer ones made by Juno Therapeutics.
|
|
Dr. Haihao Sun of the FDA's Office of Pediatric Therapeutics said the inconsistent effectiveness results were a concern to the agency.
|
|
Smaller biotech Spark Therapeutics also will seek signoff for a therapy to restore vision in an inherited form of progressive blindness.
|
|
The FDA's pending decision could have big implications for other companies developing similar treatments, such as Kite Pharma and Juno Therapeutics.
|
|
Juno Therapeutics (JUNO) ended development of an experimental leukemia drug, after the treatment's toxicity led to a number of patient deaths.
|
|
For the procedure, Hughes had her own healthy stem cells cultured at the FDA-registered biotechnology company Celltex Therapeutics in Houston.
|
|
Megan's father, John Crowley, is today the CEO of Amicus Therapeutics, a biotechnology company that specializes in therapies for rare diseases.
|
|
The venture, BlueRock Therapeutics, is expected to initially employ 30 to 40 people in Toronto, and 70 to 80 people worldwide.
|
|
The S&P 500 health care sector up more than 26 percent since Trump was inaugurated, led by a Nektar Therapeutics.
|
|
CRISPR Therapeutics announced in February that it treated a patient for sickle cell disease with gene-edited hematopoietic stem cell therapy.
|
|
CRISPR Therapeutics does not conduct any germline gene editing, the company only uses CRISPR technology to treat genetic disorders, Kulkarni said.
|
|
The sector received a fillip this week after drugmaker Roche agreed to buy gene therapy specialist Spark Therapeutics for $4.3 billion.
|
|
Sage Therapeutics — The drugmaker announced upbeat results for a phase 1.93 trial involving a new drug to treat post-partum depression.
|
|
Of those, 80 percent have even given 23andMe permission to use their genetic data for the company's new internal therapeutics team.
|
|
"Zogenix shares our deep commitment to improving treatment options for patients with rare diseases," said Joshua Grass, CEO of Modis Therapeutics.
|
|
In March, Pfizer agreed to buy gene therapies under development at French biotech Vivet Therapeutics for as much as $636 million.
|
|
PTC Therapeutics Inc, which sells another DMD treatment in Europe and certain other geographies, later bought the U.S. rights to Emflaza.
|
|
The program, called Pre-cert, will include Apple, Fitbit, Samsung, Alphabet-owned Verily, Johnson & Johnson, Pear Therapeutics, Phosphorus, Roche, and Tidepool.
|
|
"Intellia does not believe that these findings significantly impact the path forward for CRISPR-based therapeutics," it said in a statement.
|
|
It is notable that even the government does not allege that Congressman Collins traded a single share of Innate Therapeutics stock.
|
|
They have developed an evolutionary platform which can test 10 billion protein variants in one petri dish to evolve new therapeutics.
|
|
The latest example of a big outcome IPO is Rubius Therapeutics, which develops drugs based on genetically engineered red blood cells.
|
|
" Aratana Therapeutics: "I do like the pet group, and you know that I like Zoetis more and I like IDEXX Labs.
|
|
Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.) want to hear from Cigna, CVS Caremark, Humana, OptumRx and Prime Therapeutics.
|
|
Earlier this year, Albany Molecular acquired Prime European Therapeutics SpA, also known as Euticals, in a deal worth around $358 million.
|
|
That's fascinating but doesn't really benefit humans in terms of practical therapeutics, since we're not sure yet how to change ours.
|
|
Its CEO also said he was committed to the $4.3 billion Spark Therapeutics takeover, and expects it to close in 2019.
|
|
The investigation led United Therapeutics Corp in December to pay $210 million to claims related to its support of one charity.
|
|
Aldeyra Therapeutics dropped 18.6 percent to $4.15 after the company said it failed to meet a goal in its conjunctivitis trial.
|
|
Cara Therapeutics shares jumped more than 11 percent in extended trading Tuesday following the release of the company's fourth-quarter earnings.
|
|
One of Gottlieb's priorities will likely be to streamline the process for approving generic versions of complex, difficult-to-copy therapeutics.
|
|
Other companies, such as Florida startup Cyto-Sen Therapeutics, are trying natural killer cells, too, but the studies are early-stage.
|
|
BioMarin Pharmaceutical Inc and Sarepta Therapeutics Inc are developing drugs for DMD, but their treatments target a different subset of patients.
|
|
Some of its recent activist short positions include drug makers Sage Therapeutics Inc and Zafgen Inc, and satellite company Globalstar Inc.
|
|
" Cara Therapeutics: "Yeah, the stock has been hammered since we had them on, but you know what, I'm sticking by it.
|
|
Chalmers said that the medication's unique chemistry prevents it from entering the brain, a challenge Cara Therapeutics was first to meet.
|
|
One, made by Pfizer, a giant drugmaker, and Spark Therapeutics, a biotech company, is for haemophilia B, a rare bleeding disorder.
|
|
ET. * Among stocks, Global Blood Therapeutics slumped 11 percent in premarket trading after the drugmaker announced a $75 million public offering.
|
|
Aralyte is the first in a line of what Antera Therapeutics plans to be numerous early introduction products to prevent allergies.
|
|
" Sorrento Therapeutics: "Everything it tells me is that this is precisely the kind of stock that is speculative that I like.
|
|
Key digital health solutions like EHRs, digital therapeutics, telehealth, AI, wearables, and blockchain are the foundation of the industry's digital awakening.
|
|
The five approved experimental therapeutics are the monoclonal antibody cocktails ZMapp, REGN and mAb 114 and the antivirals remdesivir and favipiravir.
|
|
The first went out in May to Orexigen Therapeutics in connection with a TV ad for its weight-loss drug Contrave.
|
|
The acquisition is Aurora's second large deal this year, coming just months after it bought CanniMed Therapeutics for C$1.1 billion.
|
|
These firms are investing in companies like Alma Health, which makes coworking spaces for therapists, and the digital therapeutics startup Omada.
|
|
In addition, Nabriva Therapeutics will be eligible to receive low double-digit royalties on sales upon approval in the covered territories.
|
|
The partnership, of which the first phase is slated to last two years, will be with Clover's research subsidiary Clover Therapeutics.
|
|
Check out the companies making headlines after the bell on Wednesday: Shares of CRISPR Therapeutics plunged 83 percent in extended trading.
|
|
Mallinckrodt announced in April that it plans to change its name to Sonorant Therapeutics at some point in the near future.
|
|
One of them is Checkpoint Therapeutics, whose shares began trading on Nasdaq last June, just after Aschoff published his "buy" recommendation.
|
|
The startup claims its platform can test more than 10 billion protein variants in one petri dish to create new therapeutics.
|
|
VR therapeutics will be an area I'm looking at, and could be an alternative to more expensive healthcare devices out there.
|
|
GlaxoSmithKline and Moderna Therapeutics, using government grants, are working on RNA vaccines for Zika that are still in their early stages.
|
|
This as California legalized the recreational use of marijuana, which sent stocks like Emerald Health Therapeutics, Aurora Cannabis and Weed soaring.
|
|
Her husband sold between $1.5 million and $6 million in stock of Allogene Therapeutics, a biotech company, in January and February.
|
|
It also comes recommended by the Center for Environmental Therapeutics, a nonprofit collective of scientists and clinicians who research environmental therapies.
|
|
I asked Dr. Saward what's actually involved in fast-tracking something as sensitive and safety-focused as approval for new therapeutics.
|
|
"In the early 90s, people didn't believe antibodies could be therapeutics," Dr. Winter said during a telephone news conference on Wednesday.
|
|
A 23andMe spokesperson told CNN Business the layoffs were across the company's consumer business, but its therapeutics team was not impacted.
|
|
The spokesperson said 23andMe will continue to focus on its consumer business and therapeutics, but will dial back on clinical studies.
|
|
There, she is one of 150 students in the brand new Master of Science in Medical Cannabis Science and Therapeutics program.
|
|
Juno Therapeutics, a Seattle-based company in the space, needed to halt development for its drug therapy after three patient deaths.
|
|
Sarepta Therapeutics (SRPT) – The drugmaker received an early Food and Drug Administration approval for its second treatment for Duchenne muscular dystrophy.
|
|
The company said it entered into an option agreement to buy US Bioniz Therapeutics and to establish a broad research agreement.
|
|
Earlier that month, Astellas said it would purchase Audentes Therapeutics Inc to expand into genetic medicines, a deal worth $2.65 billion.
|
|
The app, developed by a start-up called Pear Therapeutics, is designed to be prescribed by clinician and used alongside counseling.
|
|
And Our Meg Tirrell is live at the JP Morgan Health Care Conference with the CEO of high-flying Sarepta Therapeutics.
|
|
Healthcare heavyweights Sanofi and Roche were among the biggest drags on shares amid takeover attempts of Synthorx and Spark Therapeutics, respectively.
|
|
Blueberry Therapeutics raised around $12.7 million to develop nano-medicines that treat skin and nail infections more effectively than current options.
|
|
Swiss drug maker Roche has extended its offer for its takeover of U.S. biotech firm Spark Therapeutics (ONCE) to Dec. 13.
|
|
But today, "precision" medicines — tailored therapeutics based on a patient's distinct genetic characteristics — are turning fiction into fact for many patients.
|
|
The new plea agreement with the Novelion Therapeutics Inc unit came after U.S. District Judge William Young in Boston on Oct.
|
|
Katrine was also VP, Business Development at Adnexus Therapeutics and then VP, Strategic Operations after Adnexus' acquisition by Bristol-Myers Squibb.
|
|
Source: Ian Haydon/Institute for Protein Design Natural macrocycles such as cyclosporin are among the most potent therapeutics identified to date.
|
|
The casino operator's stock will replace Nektar Therapeutics in the benchmark index, with Nektar moving to the S&IP Midcap 400.
|
|
Gottlieb is also expected to quickly act to streamline the process for approving generic versions of complex, difficult-to-copy therapeutics.
|
|
"In addition, research and development of other vaccine candidates, diagnostics, therapeutics and (mosquito) vector control technologies may be constrained," Burwell wrote.
|
|
Horizon Therapeutics (HZNP) – Horizon said an FDA advisory committee voted to recommend approval of a new treatment for thyroid eye disease.
|
|
The drug will likely be priced around $20,000 to $35,000 per treatment, Sage Therapeutics, the company that developed the drug, confirmed.
|
|
She not only founded Sirius Satellite Radio, but also founded and serves as chief executive of United Therapeutics, a pharmaceuticals company.
|
|
Speculation in the trade press on the price of Spark Therapeutics gene therapy for blindness suggest prices of up to $1,000,000.
|
|
Spark Therapeutics brought the concept into the spotlight earlier this month when it announced its Luxturna gene therapy would cost $850,000.
|
|
Why it matters: Its primary product is other biotech companies, using a "hub-and-spoke" model that already has formed such subsidiaries as Eidos Therapeutics (IPO'd last year), QED Therapeutics (launched with $65 million in funding to develop a Novartis drug) and PellePharma (signed $70 million deal with LEO Pharma that could be worth another $700 million).
|
|
Provides business update and reports third quarter 2017 financial results * TG therapeutics inc - qtrly net loss per common share $0.48 * Q3 earnings per share view $-0.43 — Thomson Reuters I/B/E/S * TG therapeutics inc - believes cash and cash equivalents will be sufficient to fund planned operations through 2018 Source text for Eikon: Further company coverage:
|
|
REPORTS BUSINESS HIGHLIGHTS AND FULL YEAR 2017 FINANCIAL RESULTS * ONCONOVA THERAPEUTICS INC - CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017, TOTALED $4.0 MILLION, COMPARED TO $21.4 MILLION AS OF DECEMBER 31, 2016 * ONCONOVA THERAPEUTICS - EXPECTS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND ONGOING TRIALS AND OPERATIONS INTO Q3 2018 Source text for Eikon: Further company coverage:
|
|
S. FDA agreed to pre-nda guidance meeting to discuss co's NDA resubmission for remoxy er as a treatment for severe chronic pain * Pain Therapeutics Inc - meeting is planned for November 14, 2017 at FDA headquarters * Pain Therapeutics Inc - remoxy NDA remains on-track for a planned resubmission in Q1 2018 Source text for Eikon: Further company coverage:
|
|
Editas is also conducting research on preventing cancer, and it is teaming up with an immunotherapy company, Juno Therapeutics, to do so.
|
|
The treatment Addie is helping test is the most advanced in a race that also includes Spark Therapeutics, UniQure, Sangamo and Pfizer.
|
|
Dowling, of the Office of Biodefense Research Resources and Translational Research, explains the agency has three research domains: diagnostics, vaccines, and therapeutics.
|
|
The shutdown has already created consequences for one drugmaker, Aimmune Therapeutics, a California-based biotech company that develops treatments for food allergies.
|
|
Its name: Cerevel Therapeutics, derived from the phrase "cerebral revelation," explained Bain Capital Life Sciences Managing Director Adam Koppel, in an interview.
|
|
Top executives of one of those drug companies, Insys Therapeutics, have pleaded not guilty to charges they paid those kickbacks and bribes.
|
|
Excluding special items, including those from acquisitions of drugmakers Five Prime Therapeutics and Cardioxyl Pharmaceuticals Inc, Bristol earned 38 cents per share.
|
|
She serves as a consultant for Aratana Therapeutics, which funded the work (not in her laboratory) using immunotherapy in dogs with osteosarcoma.
|
|
The issue of cost and profitability for MERS therapeutics is a separate issue, but this work matters for more than one infection.
|
|
Smartpatch, start-ups like Kenzen and Lief Therapeutics, are among the companies that hope to drive sales among insurers, employers and consumers.
|
|
Verve is working on those gene-editing techniques using a tool called CRISPR and is partnering with another start-up, Beam Therapeutics.
|
|
Raj Chopra, head of cancer therapeutics at the Institute of Cancer Research in London, said the NICE rejection was disappointing for patients.
|
|
Novartis is now developing Kymirah for other blood cancers, while Gilead Sciences' Kite Pharma and Juno Therapeutics are doing the same thing.
|
|
The men are listed as co-founders of Xeno Therapeutics, a medical nonprofit start-up based in Boston, according to NBC News.
|
|
"There are no proven effective therapeutics for novel coronavirus," Dr. Mike Ryan, executive director of WHO emergencies program, told a news conference.
|
|
Shares of Juno Therapeutics gained nearly 10.5 percent Monday after the company released promising clinical data for one of its leukemia treatments.
|
|
Sébastien has invested in more than 30 companies and is currently board member of Balyo, Global Bioenergies, Eligo, Domain Therapeutics and Skinjay.
|
|
Global Blood Therapeutics – The drug maker announced positive results in a late-stage clinical trial for its experimental sickle-cell disease treatment.
|
|
He is founder and director of Tvardi Therapeutics, which is developing a targeted therapy for STAT3 in cancer and non-cancer indications.
|
|
Companies with gene-editing platforms including Editas Medicine and CRISPR Therapeutics saw their shares jump after Gilead signaled interest in the technology.
|
|
Both Editas and Crispr Therapeutics are investigating how their technologies might work for DMD, but they're currently only in the discovery phase.
|
|
The companies — CVS Health, Cigna, Prime Therapeutics, Humana and OptumRx, a subsidiary of UnitedHealthcare — claimed they do not contribute to skyrocketing prices.
|
|
Aimmune Therapeutics is behind the drug, called Palforzia, which exposes patients to small amounts of peanuts and helps build up their resistance.
|
|
She said a lack of funding could also halt the development of other vaccines, as well as diagnostics, therapeutics and mosquito control.
|
|
BOSTON (Reuters) - A federal judge on Tuesday expressed concern about the scope of an indictment against several former Insys Therapeutics Inc INSY.
|
|
"It's now an arms race," said Sabah Oney, a geneticist and business development lead at Alector, a Silicon Valley-based therapeutics company.
|
|
On Tuesday, the trader scooped up shares of Amicus Therapeutics, a biotechnology firm involved in the development of drugs for rare diseases.
|
|
In November, the Cambridge, Massachusetts-based company merged with QLT Inc and became a subsidiary of the newly named Novelion Therapeutics Inc.
|
|
TG Therapeutics jumped 14.1 percent to $15.80 after the drugmaker's data from the trial of its experimental cancer drug yielded positive results.
|
|
Alkermes gets most of its revenue from royalties on drugs such as Acorda Therapeutics Inc's multiple sclerosis drug and AstraZeneca's diabetes treatment.
|
|
In September, the FDA approved the first mobile app to treat certain substance use disorders, developed by the Boston company Pear Therapeutics.
|
|
In July, she is to become the director of business development and operations at Carmot Therapeutics in San Francisco, a biopharmaceutical company.
|
|
The animal lived an average of just 36 hours, according to the research paper that was published to CNS Neuroscience and Therapeutics.
|
|
AmerisourceBergen, the Blue Cross Blue Shield Association, Pfizer and Prime Therapeutics are partnering with Walgreens to add kiosks to another 900 stores.
|
|
MS, GS. Halozyme Therapeutics (US, biotech) – $400m 5y cvt priced at 83%, up 35% versus talk of 1%-1.5% and 35%-40%.
|
|
XBI surged more than 2 percent on Tuesday morning as pharma giant Allergan reached a $1.7 billion deal to buy Tobira Therapeutics.
|
|
Sage Therapeutics said Thursday its drug to treat moderate and severe postpartum depression met the main goal in two late-stage studies.
|
|
Juno Therapeutics, the company conducting the clinical trial, said on Thursday that the Food and Drug Administration had temporarily halted the study.
|
|
Drug developer Juno Therapeutics said it halted a mid-stage study on a potential leukemia treatment following the deaths of two patients.
|
|
While Groups is focused on a new type of clinic, Boston-based Pear Therapeutics is designing mobile apps to help treat addiction.
|
|
Astra last year invested a further $140 million in messenger RNA specialist Moderna Therapeutics, lifting its stake in Moderna to 9 percent.
|
|
"Tatiana was a bright and passionate rising star on our Nektar Investor Relations team," said Jennifer Ruddock, a spokeswoman for Nektar Therapeutics.
|
|
Other companies, such as Mirati Therapeutics Inc, are also developing drugs that target KRAS mutations, but Amgen's could be first to market.
|
|
Competitor Juno Therapeutics Inc gave up earlier this year on developing CAR-T candidate JCAR015 for ALL after toxicities and patient deaths.
|
|
Assertio Therapeutics, previously known as Depomed, explored a sale three years ago under pressure from Starboard but did not reach any deal.
|
|
That includes Intellia and Crispr Therapeutics—companies cofounded by Doudna and Charpentier respectively—which are both developing Crispr treatments for human disease.
|
|
As for venture deals, beside backing Celularity last month, Celgene also just led a $100 million financing for drug developer Vividion Therapeutics.
|
|
Indicated 0.2 percent higher The company said it was partnering with Mirati Therapeutics to develop a novel companion diagnostic for lung cancer.
|
|
As in past quarters, a high portion of the largest early-stage fundings went to life science companies developing breakthrough therapeutics platforms.
|
|
Among others, PTC Therapeutics Inc has an approved drug for the disease, while Solid Biosciences is developing a gene therapy for DMD.
|
|
The focus was intended to be on efforts to fast-track antiviral treatments and therapeutics for those suffering from the novel coronavirus.
|
|
Feinstein, one the longest-tenured Senate Democrats, sold at least $500,000 in shares of Allogene Therapeutics, a California biotechnology company, on Jan.
|
|
Spark Therapeutics – Spark and Switzerland's Roche announced another extension of Roche's $4.3 billion takeover bid for the U.S.-based gene therapy company.
|
|
Spark Therapeutics (ONCE) and Switzerland's Roche announced another extension of Roche's $4.3 billion takeover bid for the U.S.-based gene therapy company.
|
|
Similar "pharmacy and therapeutics" (P&T) committees at rivals CVS Health Corp and Cigna Inc's Express Scripts came to the same conclusion.
|
|
In 2017, United Therapeutics paid $210 million to settle similar allegations, and Pfizer paid nearly $24 million to do so in May.
|
|
The charity was also involved in the settlement with United Therapeutics, which, like Actelion, sells drugs that treat the same lung condition.
|
|
It will also provide additional resources for states and assist federal efforts to develop vaccines and therapeutics, as well as hospital preparedness.
|
|
Our foundation is working with all the groups who make diagnostics, therapeutics and vaccines to make sure the right efforts are prioritized.
|
|
HHS Secretary Alex Azar: Scientists in America and around the world have identified multiple potential therapeutics for #COVID19, including chloroquine and hydroxychloroquine.
|
|
Acorda Therapeutics (ACOR) is seeing its shares jump on news that investor Steven Cohen's Point72 disclosed a 9.8% stake in the drugmaker.
|
|
Already, they are reeling from the decision by PTC Therapeutics to price a once-cheap steroid, deflazacort, at about $35,000 per year.
|
|
The groom's mother retired as the vice president of quality at Acorda Therapeutics, a biotechnology company, in the South San Francisco office.
|
|
The company plans to tighten its focus on the DTC business and its therapeutics arm while scaling back its clinical studies arm.
|
|
The casino operator's stock will replace Nektar Therapeutics (NKTR) in the benchmark index, with Nektar moving to the S&P Midcap 400.
|
|
In 2015, Julie led the Series C financing for Protagonist Therapeutics (PTGX), which is developing orally stable peptides to treat autoimmune disorders.
|
|
Intarcia Therapeutics, a Gates Foundation-backed biotech, is developing implantable devices intended to treat conditions like Type 2 diabetes and prevent HIV.
|
|
Audentes Therapeutics (BOLD) – Audentes agreed to be bought by Japan's Astellas Pharma for about $3 billion in cash or $60 per share.
|
|
Celgene — Celgene announced Monday that its offer to buy the rest of Juno Therapeutics for $87 a share expired Saturday at midnight.
|
|
CEO and founder Jessica Richman said in a statement that uBiome will now begin to develop therapeutics from its deep data sources.
|
|
"Everyone is trending up in this area," said Jeremy Jenkins, the head of data science for chemical biology and therapeutics at Novartis.
|
|
As for the new treatment approach targeting a specific gene mutation, "we're in a new era of therapeutics for neurological disease," he said.
|
|
Denenberg, a partner at Davis Polk & Wardell, has worked on IPOs of companies such as Twitter, Roku, Yelp, Unity Biotechnology and Akcea Therapeutics.
|
|
Sage Therapeutics climbed slightly after the drugmaker announced positive results for a phase 2 trial involving a new drug to treat postpartum depression.
|
|
Zogenix — The pharmaceutical company's stock dropped more than 8% on news it will acquire Modis Therapeutics for $250 million in cash and stock.
|
|
Sarepta Therapeutics (SRPT) was soaring in premarket trading, after the FDA asked for more information on the company's experimental treatment for muscular dystrophy.
|
|
However, investors saw the results as potentially warning about the entire area of microbiome therapeutics, which has been looked on with much promise.
|
|
Other firms specializing in CAR-T such as Juno Therapeutics have signed deals to use another kind of gene-editing technology called CRISPR.
|
|
Sarepta Therapeutics — Sarepta Therapuetics soared more than 17% on Friday after a potential competitor drug from Pfizer showed side effects in a study.
|
|
The IBB was helped by shares of Sarepta Therapeutics and Incyte, which had gained as much as 9 percent and 7 percent, respectively.
|
|
According to CB Insights, a research firm, equity investment in cancer-therapeutics startups has grown from $22016bn in 22.5 to $4.5bn in 2017.
|
|
O) has discussed a sale of Paladin Labs Inc, its Montreal-based specialty pharmaceutical subsidiary, to Canadian drug maker Knight Therapeutics Inc (GUD.
|
|
Last year, Novartis acquired Admune Therapeutics and forged licensing agreements with small drug developers Xoma and Palobiofarma as part of this same push.
|
|
Sage Therapeutics is developing another drug that affects GABA, similar to brexanolone, but which can be taken orally—as are other drug companies.
|
|
Spark Therapeutics is charging $850,000 for its recently approved gene therapy drug, Luxturna, which treats a rare eye condition that leads to blindness.
|
|
Indicated 20.8916 percent higher Evotec said it had agreed deeper cooperation with Carrick Therapeutics, in which it would invest up to $6 million.
|
|
Shares of Tobira Therapeutics rose more than six times to $32.55 after Allergan agreed to buy the company in a $1.7 billion deal.
|
|
In a major deal-- in the drug sector, Roche is buying Spark Therapeutics for $783 billion, about 773-- $763 a share for Spark.
|
|
And the people who do really well in that business do maintenance therapeutics and they can keep people alive for a long time.
|
|
Over the last year, tie-ups have emerged between Bristol-Myers Squibb and Celgene, Shire and Takeda, Roche and Spark Therapeutics among others.
|
|
Assertio Therapeutics Inc, previously known as Depomed, explored a sale three years ago under pressure from Starboard but did not reach any deal.
|
|
A 2006 studypublished in the Journal of Ocular Pharmacology and Therapeutics, for example, said 15 microliter drops are as effective as large drops.
|
|
That's the goal of Moderna Therapeutics, the Cambridge, Massachusetts-based company that's been developing its messenger RNA (mRNA) since its founding in 2010.
|
|
In 13 Johnson & Johnson-owned Janssen Therapeutics' got fast-track FDA conditional approval for this drug for use in adults with MDR-TB.
|
|
The company competes in the race for mRNA therapies with groups such as Massachusetts-based Moderna Therapeutics, Belgium's eTheRNA and domestic rival CureVac.
|
|
Spark Therapeutics (ONCE) received a positive recommendation from an FDA panel on its gene therapy treatment for a rare form of vision loss.
|
|
A study in Clinical Therapeutics about a decade ago specifically compared the rates of cost-related nonadherence in the United States and Canada.
|
|
Revance Therapeutics' wrinkle-reducing injection met its goal of lasting for six months, according to phase three trial results the company released Tuesday.
|
|
In 8003, Celgene has tried to turn things around, acquiring cancer immunotherapy company Juno Therapeutics, then partnering with Prothena on neuro-degenerative treatments.
|
|
Among stocks making big moves, Juno Therapeutics soared $2.63, or 9.5 percent, to $30.42 after regulators said its leukemia drug trials can continue.
|
|
In 2010, he started his doctorate in the health, science, and technology program at MIT, focusing his research on developing therapeutics for hearing.
|
|
As he was finishing the program in 2016, Whitton was approached by Decibel Therapeutics and hired to work on therapies for hearing loss.
|
|
Once the F.D.A. gave final approval to Subsys in early 2012, the fate of Insys Therapeutics rested on selling it in the field.
|
|
Sage Therapeutics slumped more than 19 percent after its drug to treat a life-threatening seizure disorder failed in a late-stage trial.
|
|
Sarepta Therapeutics CEO Douglas Ingram told CNBC that more tests are needed to develop a gene therapy to treat a rare genetic disease.
|
|
"I call it a Frankenstein-like molecule," said Dr. Renier J. Brentjens, the director of cellular therapeutics at Memorial Sloan Kettering Cancer Center.
|
|
Nektar Therapeutics – An experimental pneumonia treatment developed by Nektar and partner Bayer did not meet its primary goal in a phase III study.
|
|
Intarcia Therapeutics, a Gates Foundation-backed biotech, is developing implantable devices intended to treat conditions like Type 2 diabetes and to prevent HIV.
|
|
The drug developer Sarepta Therapeutics plunged after a Food and Drug Administration panel said its muscular dystrophy drug eteplirsen should not be approved.
|
|
Acorda Therapeutics — The drugmaker will cut nearly 20 percent of its workforce, in a move expected to save more than $21 million annually.
|
|
Separately, U.S. biotech company Mirati Therapeutics said it reached a clinical collaboration agreement with Novartis to evaluate a specific combination of cancer treatments.
|
|
Sophia Genetics is a leader in the preventive and personalized medicine revolution, enabling the development of targeted therapeutics, thereby vastly improving health outcomes.
|
|
Check out the companies making headlines after the bell Tuesday: Shares of Juno Therapeutics soared close to 40 percent in the extended session.
|
|
The owner of Insys Therapeutics, which makes Subsys — and five prescribing doctors — were charged in a bribery scheme to boost off-label prescribing.
|
|
The contribution from Zuckerberg and his wife comes after the Bill & Melinda Gates Foundation launched the COVID-19 Therapeutics Accelerator earlier in March.
|
|
The Justice Department in April accused Insys Therapeutics of paying kickbacks to induce doctors to prescribe its powerful opioid painkiller for their patients.
|
|
But in thinking about personalized medicine and therapeutics, in order to change patients' mutations, we will have to do it in the cytoplasm.
|
|
This combination of electric power and solar charging is crucial to Beta's primary client, United Therapeutics, which provided the initial funding for Beta.
|
|
Currently, there is no vaccine to combat it, nor any approved therapeutics to slow the course of its toll on the human body.
|
|
Medicenna Therapeutics Corp: * MEDICENNA REPORTS THIRD QUARTER FISCAL 2020 FINANCIAL RESULTS * QTRLY LOSS PER SHARE $0.07 Source text for Eikon: Further company coverage:
|
|
The White House is seeking a total of $2.5 billion from Congress to develop a vaccine, invest in therapeutics, and stockpile masks.5.
|
|
Government scientists as well as those working at Johnson & Johnson, Moderna Therapeutics and Inovio Pharmaceuticals are all working quickly to develop a vaccine.
|
|
The trial is being expanded to include more patients and is being conducted by Vertex Pharmaceuticals and CRISPR Therapeutics of the Boston area.
|
|
Amicus Therapeutics – The drugmaker will submit a new drug application for its treatment of Fabry disease during the fourth quarter of this year.
|
|
Some patients have died, including five in recent months in clinical trials of a new immunotherapy drug being tested by Juno Therapeutics Inc.
|
|
" They added: "It is notable that even the government does not allege that Congressman Collins traded a single share of Innate Therapeutics stock.
|
|
Fidelity funds stayed on the sidelines as shares of Aclaris Therapeutics Inc skyrocketed after the drug maker listed its stock in October 210.
|
|
Healthcare analyst Ritu Baral of Cowen & Co. Her favorite stocks right now include SAGE Therapeutics (SAGE); Cytokinetics Inc (CYTK); and Intercept Pharma (ICPT).
|
|
Since January 28, Feinstein's investment banker husband, Richard Blum, has twice sold stock in San Francisco-based Allogene Therapeutics, according to disclosure forms.
|
|
S) sliding after it agreed to extend the deadline for its $4.3 billion takeover bid for U.S. gene therapy specialist Spark Therapeutics (ONCE.
|
|
On March 16, 7816, Nabriva Therapeutics entered into a Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co., as agent, pursuant to which Nabriva Therapeutics may offer and sell its ordinary shares, nominal value $0.01 per share, for aggregate gross sale proceeds of up to $50,000,000 from time to time through Cantor Fitzgerald under an "at-the-market" (ATM) offering program.
|
|
The firm&aposs head of investor relations and marketing, Patrick Murrow, told Business Insider that its biggest public positions drove performance — naming companies such as Global Blood Therapeutics, which had a drug for sickle-cell disease approved by the FDA in November, and Mirati Therapeutics, which saw its stock jump 28% in December thanks to a study on an ovarian cancer drug.
|
|
Shares of Athenex, Urogen and G1 Therapeutics, three cancer drug developers that went public this past quarter, have held up well in aftermarket trading.
|
|
She holds a B.A. in human biology from Stanford University, and her recent investments include Annum Health, Dauntless, PACT Pharma, Tizona Therapeutics and Vineti.
|
|
It's a model Pfizer appears increasingly to be exploring: Last fall, Pfizer spun out Springworks Therapeutics, along with rights to four of its programs.
|
|
Pfizer — Gene therapy company Spark Therapeutics received a $15 million payment from Pfizer for continued progress in developing a landmark medication to combat hemophilia.
|
|
Liu is a consultant and co-founder of Prime Medicine, Beam Therapeutics, Pairwise Plants and Editas Medicine, which are companies that use genome editing.
|
|
Executives from CVS Health, Cigna, Prime Therapeutics, Humana and UnitedHealth's OptumRx testified about rising prescription drug costs before the Senate Finance Committee on Tuesday.
|
|
"Subcutaneous dosing with Coversin will represent an important advance for patients in complement therapy," said Dr. Gur Roshwalb, Chief Executive Officer of Akari Therapeutics.
|
|
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.
|
|
Sarepta Therapeutics – Sarepta said the U.S. Food and Drug Administration did not approve its new treatment for Duchenne muscular dystrophy, pointing to safety concerns.
|
|
Jonas, who's an M.D., also spoke about the various catalysts and products for Sage Therapeutics, particularly a drug that aims to treat severe seizures.
|
|
Shares of Sarepta Therapeutics fell nearly 26 percent Thursday as the Food and Drug Administration finalized new procedures for expanded access for unapproved drugs.
|
|
RECEIVE REQUEST FOR ADDITIONAL INFORMATION FROM FTC UNDER HART-SCOTT-RODINO ACT AND ANNOUNCE EXTENSION OF TENDER OFFER FOR SHARES OF SPARK THERAPEUTICS, INC.
|
|
In July, the FDA similarly placed a hold on clinical trials of another leukemia treatment from the company Juno Therapeutics after two patient deaths.
|
|
Intellia Therapeutics is hoping to transform the future of medicine with its gene-editing technology, which its CEO likened to a pair of scissors.
|
|
Shares of Sarepta Therapeutics briefly surged more than 90 percent Monday after the Food and Drug Administration approved the company's muscular dystrophy drug eteplirsen.
|
|
One speculative biotech that landed on Cramer's radar was Seres Therapeutics, which traded between $20 and the mid-$30s until July, when disaster struck.
|
|
Allergan also announced it would buy Tobira Therapeutics for what could be as much as $1.7 billion, a 700 percent premium for the company.
|
|
Verve Therapeutics, a biotech firm in Cambridge, Massachusetts, recently said that it wanted to use genetic editing to protect patients from coronary heart disease.
|
|
CRISPR Therapeutics, based in Zug, Switzerland, wants to edit beta cells, which produce insulin, so that they can be transplanted into diabetics without rejection.
|
|
He is also a co-founder of G1 Therapeutics, a biotech firm focused on cancer treatment therapies that went public in May of 2017.
|
|
A range of startups are leading the charge in digital therapeutics, tackling some of the biggest problems facing patients and our healthcare system today.
|
|
CNBC's Meg Tirrell sits down with Synthego CEO Paul Dabrowski, CEO, Standford Medical School's Dr. William Hurlbut and CRISPR Therapeutics CEO Dr. Samarth Kulkarni.
|
|
Alphabet funds struck venture deals with 11 other companies that have since gone public, including Baidu, HubSpot, Cloudera, Spero Therapeutics, Lending Club and Zynga.
|
|
In corporate news, the Danish firm Novo Nordisk has begun talks with Global Blood Therapeutics, a U.S. company, for a potential acquisition, Reuters reported.
|
|
I spoke to YourChoice Therapeutics, a startup developing unisex, non-hormonal birth control, and Bottomless, which operates a direct-to-consumer coffee delivery service.
|
|
Crispr-based therapeutics are just beginning clinical trials in the US, but pricing a genetic cure is already challenging the pharma and insurance industries.
|
|
Ascentage, which focuses on therapeutics for cancers, hepatitis B and aging-related diseases, is aiming to raise up to $300 million, two sources said.
|
|
Celgene is in discussions to buy Juno Therapeutics roughly a week after agreeing to acquire a separate drug company, the Wall Street Journal reports.
|
|
The acquisition comes at a testing moment for cell therapy, following the deaths of three leukemia patients in a trial of Juno Therapeutics' JUNO.
|
|
The pharmaceutical company that produces the treatment, Spark Therapeutics, notes on its website that it assists by directly contacting insurers and offers payment plans.
|
|
On Wednesday, Cramer spoke with Dr. Derek Chalmers, the co-founder and CEO of Cara Therapeutics to get a take on the pharma space.
|
|
The idea is similar to Emerald Cloud Therapeutics or another YC company, Transcriptic in that customers can order services needed through an online platform.
|
|
A third company, Juno Therapeutics, halted the development of one its CAR T-cell therapies after five patients died from complications of the treatment.
|
|
Sage Therapeutics, a biopharmaceutical company that develops medicines to treat central nervous disorders, has been in the news lately for two very different reasons.
|
|
The FDA's move seems to be intended to soften the repercussions of its possible rejection of Sarepta Therapeutics Inc's muscle-wasting drug, analysts said.
|
|
Among the most successful recent innovations in cancer therapeutics is immunotherapy, in which a patient's own immune system is activated to target cancer cells.
|
|
One of the keynote speakers was Dr. Martine Rothblatt, the chief executive of United Therapeutics and the author of "Virtually Human," who is transgender.
|
|
A start-up called Chrono Therapeutics is working towards FDA approval for its wearable quit-smoking system, which delivers nicotine via a programmed patch.
|
|
Athena Countouriotis: President, C.E.O., Turning Point Therapeutics As a mother, business leader and physician, I try to remain positive in the face of adversity.
|
|
The promise of this voucher has allowed Abeona Therapeutics to continue to raise money from investors, including George Soros, to begin the clinical trial.
|
|
Additionally, the firm will lobby for Prime Therapeutics, which works on pharmacy benefit management, issues relating to pharmaceutical value-based contracting and rebate transparency.
|
|
The biotech Spark Therapeutics needed a way to measure improvements to a patient's vision when testing a new treatment for a rare eye disorder.
|
|
United Therapeutics, based in Silver Spring, Maryland, previously disclosed in July that it had set aside $210 million amid talks to resolve the investigation.
|
|
The mutation affects both eyes, usually at the same pace, so most patients would need treatment for both eyes, a Spark Therapeutics spokeswoman said.
|
|
"We do not believe the theoretical risks described in these papers apply to CRISPR Therapeutics' programs," the company said in a statement to CNBC.
|
|
In corporate news, Sage Therapeutics skyrocketed 70 percent after announcing positive results from Phase 2 testing of its depression drug known as SAGE-217.
|
|
S) and Fujifilm Holdings - which in 2015 bought Cellular Dynamics International Inc - in the race, as well as biotech firms including Fate Therapeutics (FATE.
|
|
Sage Therapeutics has to balance two competing interests when it comes to pricing its postpartum depression drug, CEO Jeff Jonas told CNBC on Wednesday.
|
|
BUY TICKETS HERE Arthro Therapeutics DPOrganizer Guestrument Lifee AB Mentimeter MIND Music Labs Peppy Pals Touchtech ABP Vainu Workaround Sponsors make TechCrunch events possible.
|
|
There are five big areas that I am particularly excited about: consumer VR experiences, the VR office, VR retail, VR therapeutics and VR toolboxes.
|
|
Shares of Sage Therapeutics soared 70 percent on Thursday after the company announced positive results in the testing a major depressive disorder (MDD) treatment.
|
|